PART 1: FINANCIAL INFORMATION

Item 1. Financial Statements

Fennec Pharmaceuticals Inc.

Condensed Consolidated Balance Sheets

(U.S. Dollars and shares in thousands)

(Unaudited)

September 30, 2017 December 31,
(unaudited) 2016

Assets

Current assets:
Cash and cash equivalents $ 9,688 $ 3,926
Prepaid expenses 198 43
Other current assets 2 3
Total assets $ 9,888 $ 3,972

Liabilities and stockholders' equity

Current liabilities:
Accounts payable $ 492 $ 244
Accrued liabilities 165 125
Derivative instruments (Note 4) 373 33
Total current liabilities 1,030 402

Total liabilities 1,030 402

Commitments and contingencies (Note 8)

Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 15,857 shares issued and outstanding (2016-13,643) 83,062 74,515
Additional paid-in capital 43,631 42,134
Accumulated deficit (119,078 ) (114,322 )
Accumulated other comprehensive income 1,243 1,243
Total stockholders’ equity 8,858 3,570
Total liabilities and stockholders’ equity $ 9,888 $ 3,972


	September 30,		December 31,
	2023		2022

Assets
Current assets
Cash and cash equivalents	$	12,399	$	23,774
Accounts receivable, net		4,525		1,545
Prepaid expenses		247		770
Inventory		1,755		576
Other current assets		20		63
Total current assets		18,946		26,728

Non-current assets
ROU asset non-current		29		—
Deferred issuance costs, net of amortization		53		211
Total non-current assets		82		211
Total assets	$	19,028	$	26,939

Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable	$	2,941	$	2,390
Accrued liabilities		951		2,219
Operating lease liability - current		21		—
Total current liabilities		3,913		4,609

Non-current liabilities
Term loan		25,000		25,000
PIK interest		937		260
Debt discount		(298)		(361)
Operating lease liability - net of current portion		7		—
Total non-current liabilities		25,646		24,899
Total liabilities		29,559		29,508

Commitments and contingencies (Note 6)

Stockholders’ deficit:
Common stock, no par value; unlimited shares authorized; 26,635 shares issued and outstanding (2022 ‑ 26,361)		143,560		142,591
Additional paid-in capital		61,229		56,797
Accumulated deficit		(216,563)		(203,200)
Accumulated other comprehensive income		1,243		1,243
Total stockholders’ deficit		(10,531)		(2,569)
Total liabilities and holders’ deficit	$	19,028	$	26,939

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statements.

Table of Contents

Fennec Pharmaceuticals Inc.

Condensed Consolidated Statements of Operations

(U.S. Dollars and shares in thousands, except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended
September 30, September 30, September 30, September 30,
2017 2016 2017 2016

Revenue $ - $ - $ - $ -

Operating expenses:
Research and development 492 112 1,050 298
General and administrative 1,694 452 3,386 1,427

Loss from operations (2,186 ) (564 ) (4,436 ) (1,725 )

Other (expense) income :
Unrealized (loss)/gain on derivatives (Note 4) (183 ) 19 (340 ) 45
Sale of Eniluracil - 40 - 40
Other gain/(loss) 1 - (4 ) (12 )
Interest income and other 16 3 24 6
Total other (expense)/income, net (166 ) 62 (320 ) 79

Net loss $ (2,352 ) $ (502 ) $ (4,756 ) $ (1,646 )

Basic net loss per common share $ (0.15 ) $ (0.04 ) $ 0.32 $ (0.13 )
Diluted net loss per common share $ (0.15 ) $ (0.04 ) $ 0.32 $ (0.13 )
Weighted-average number of common shares outstanding, basic 15,740 13,643 14,533 12,469
Weighted-average number of common shares outstanding, diluted 15,740 13,643 14,533 12,469


	Three Months Ended				Nine Months Ended
	September 30,		September 30,		September 30,		September 30,
	2023		2022		2023		2022

Revenue
PEDMARK® product sales, net	$	6,515	$	—	$	11,517	$	—
Cost of products sold		(331)		—		(574)		—
Gross profit		6,184		—		10,943		—

Operating expenses:
Research and development		12		846		24		3,414
Selling and marketing		3,384		—		8,255		—
General and administrative		3,805		7,053		13,617		13,040

Total operating expenses		7,201		7,899		21,896		16,454
Loss from operations		(1,017)		(7,899)		(10,953)		(16,454)

Other (expense)/income
Realized foreign exchange (loss)/gain		(11)		(4)		3		(6)
Amortization expense		(72)		(64)		(217)		(79)
Unrealized loss on securities		(13)		(27)		(43)		(126)
Interest income		102		24		326		42
Interest expense		(856)		(119)		(2,479)		(234)
Total other expense		(850)		(190)		(2,410)		(403)
Net loss	$	(1,867)	$	(8,089)	$	(13,363)	$	(16,857)

Basic net loss per common share	$	(0.07)	$	(0.31)	$	(0.50)	$	(0.65)
Diluted net loss per common share	$	(0.07)	$	(0.31)	$	(0.50)	$	(0.65)
Weighted-average number of common shares outstanding basic		26,596		26,108		26,523		26,105
Weighted-average number of common shares outstanding diluted		26,596		26,108		26,523		26,105

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statements.

Table of Contents

Fennec Pharmaceuticals Inc.

Condensed Consolidated Statements of Stockholders’ Equity

Three and Nine Months Ended September 30, 2023, and 2022

(U.S. dollars and shares in thousands)

(Unaudited)


								Accumulated
				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Income		Equity

Balance at December 31, 2022	26,361	$	142,591	$	56,797	$	(203,200)	$	1,243	$	(2,569)
Stock-based compensation - employees	—		—		1,089		—		—		1,089
Stock option exercise	49		213		—		—		—		213
Restricted stock release	1		—		(20)		—		—		(20)
Net loss	—		—		—		(6,052)		—		(6,052)
Balance at March 31, 2023	26,411		142,804		57,866		(209,252)		1,243		(7,339)
Stock-based compensation - employees	—		—		2,543		—		—		2,543
Stock option exercise	95		541		—		—		—		541
Restricted stock release	3		—		(28)		—		—		(28)
Net loss	—		—		—		(5,444)		—		(5,444)
Balance at June 30, 2023	26,509		143,345		60,381		(214,696)		1,243		(9,727)
Stock-based compensation - employees	—		—		865		—		—		865
Stock option exercise	92		215		—		—		—		215
Restricted stock release	32		—		(17)		—		—		(17)
Net loss	—		—		—		(1,867)		—		(1,867)
Balance at September 30, 2023	26,633	$	143,560	$	61,229	$	(216,563)	$	1,243	$	(10,531)


								Accumulated
				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Income		Equity
Balance at December 31, 2021	26,014	$	140,801	$	53,214	$	(179,486)	$	1,243	$	15,772
Stock-based compensation - employees	—		—		399		—		—		399
Stock-based compensation - consultants	—		—		34		—		—		34
Stock option exercise	26		31		(16)		—		—		15
Restricted stock release	—		—		—		—		—		—
Net loss	—		—		—		(3,696)		—		(3,696)
Balance at March 31, 2022	26,040		140,832		53,631		(183,182)		1,243		12,524
Stock-based compensation - employees	—		—		1,008		—		—		1,008
Stock-based compensation - consultants	—		—		35		—		—		35
Stock option exercise	19		90		(44)		—		—		46
Restricted stock release	8		—		—		—		—		—
Net loss	—		—		—		(5,072)		—		(5,072)
Balance at June 30, 2022	26,067		140,922		54,630		(188,254)		1,243		8,541
Stock-based compensation - employees	—		—		1,853		—		—		1,853
Stock-based compensation - consultants	—		—		34		—		—		34
Warrants issued to creditor	—		—		441		—		—		441
Stock option exercise	151		387		(199)		—		—		188
Restricted stock release	20		—		(166)		—		—		(166)
Net loss	—		—		—		(8,089)		—		(8,089)
Balance at September 30, 2022	26,238	$	141,309	$	56,593	$	(196,343)	$	1,243	$	2,802

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Fennec Pharmaceuticals Inc.

Condensed Consolidated Statements of Cash Flows

(U.S. Dollars in thousands)

(Unaudited)

Three Months Ended Nine Months Ended
September 30, September 30, September 30, September 30,
2017 2016 2017 2016
Cash flows used in:
Operating activities:
Net loss $ (2,352 ) $ (502 ) $ (4,756 ) $ (1,646 )
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss/(gain) on derivative 183 (19 ) 340 (45 )
Stock-based compensation - contractors 210 28 552 58
Stock-based compensation - employees 907 41 1,409 152
Changes in operating assets and liabilities:
Prepaid assets (177 ) (23 ) (155 ) 35
Other current assets 4 3 1 (1 )
Accounts payable 196 (110 ) 248 (62 )
Accrued liabilities 71 38 40 (4 )

Net cash used in operating activities (958 ) (544 ) (2,321 ) (1,513 )

Financing activities:
Options and warrants exercised 383 - 512 108
Private placement 31 - 7,571 5,000

Net cash provided by financing activities 414 - 8,083 5,108

Increase in cash and cash equivalents (544 ) (544 ) 5,762 3,595
Cash and cash equivalents - Beginning of period 10,232 5,081 3,926 942
Cash and cash equivalents - End of period $ 9,688 $ 4,537 $ 9,688 $ 4,537


	Nine Months Ended
	September 30,		September 30,
	2023		2022

Cash flows (used in) provided by:
Operating activities:
Net loss	$	(13,363)	$	(16,857)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt access fees		166		77
Amortization of debt discount		51		2
Unrealized loss on securities		43		126
Stock-based compensation - consultants		—		103
Stock-based compensation - employees		4,497		3,260
Changes in operating assets and liabilities:
Accounts receivable		(2,980)		—
Prepaid expenses		523		756
Inventory		(1,179)		—
Other assets		—		4
Accounts payable		551		1,756
Accrued liabilities and PIK interest		(592)		(483)
Net cash used in operating activities		(12,283)		(11,256)

Financing activities:
Long-term debt		—		25,000
Long-term debt paid		—		(5,000)
Issuance of shares, options exercise		969		249
Cash paid for taxes on restricted share release		(61)		(166)
Capitalized deferred issuance costs		—		(175)
Net cash provided by financing activities		908		19,908

Increase/(decrease) in cash and cash equivalents		(11,375)		8,652
Cash and cash equivalents - Beginning of period		23,774		21,100
Cash and cash equivalents - End of period	$	12,399	$	29,752

Non-cash investing and financing activities:
Capitalized lease asset	$	29	$	—
Warrants issued for long-term debt	$	—	$	441

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statement.

Table of Contents

~~Fennec Pharmaceuticals Inc.~~

~~Condensed Consolidated Statements of Stockholders' Equity~~

~~(U.S. dollars and shares in thousands)~~

~~(Unaudited)~~

Accumulated
Additional Other Total
Common Stock Paid-in Accumulated Comprehensive Stockholders'
Number (Note 6) Amount Capital Deficit Income Equity

Balance at December 31, 2016 13,643 74,515 42,134 (114,322 ) 1,243 3,570
Stock options issued to employees - - 41 - - 41
Stock options issued to contractors - - 56 - - 56
Net loss - - - (806 ) - (806 )
Balance at March 31, 2017 13,643 74,515 42,231 (115,128 ) 1,243 2,861
Stock options issued to employees - - 461 - - 461
Stock options issued to contractors - - 286 - - 286
Exercise of stock options 86 191 (93 ) - - 98
Rights offering 1,900 7,571 - - - 7,571
Net loss - - - (1,598 ) - (1,598 )
Balance at June 30, 2017 15,629 82,277 42,885 (116,726 ) 1,243 9,679
Stock options issued to employees - - 907 - - 907
Stock options issued to contractors - - 210 - - 210
Exercise of stock options 207 743 (360 ) - - 383
Exercise of warrants 21 42 (11 ) - - 31
Net loss - - - (2,352 ) - (2,352 )
Balance at September 30, 2017 15,857 83,062 43,631 (119,078 ) 1,243 8,858

~~The accompanying notes are an integral part of these unaudited condensed consolidated financial statements~~

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Nature of Business and Going Concern

Fennec Pharmaceuticals Inc., a corporation existing under the laws of British Columbia (“~~Fennec”~~Fennec,” the “Company,” “we,” “us,” or “our”), was originally formed under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec is a ~~British Columbia corporation. Fennec, together~~commercial stage specialty pharmaceutical company with ~~its~~one U.S. Food and Drug Administration (“FDA”) approved and European Commission approved product , PEDMARK^®, developed to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. The Company has four wholly owned ~~subsidiaries~~subsidiaries: Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, ~~and~~ Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), an Ireland company, collectively referred to herein as the ~~“Company,~~“Company.” ~~is a biopharmaceutical company focused on the development of PEDMARK~~^TM~~(a unique formulation of Sodium Thiosulfate (“STS”)) for the prevention of ototoxicity from cisplatin in pediatric patients.~~ With the exception of Fennec Pharmaceuticals, Inc., and Fennec Pharmaceuticals (EU) all subsidiaries are inactive.

These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

During the three and nine months ended September 30, ~~2017,~~2023, the Company incurred a loss from operations of ~~$4,436.~~$1,017 and $10,953, respectively. At September 30, ~~2017,~~2023, it had an accumulated deficit of ~~$119,078~~$216,563 and had experienced negative cash flows from operating activities during the nine months ended September 30, ~~2017~~2023, in the amount of ~~$2,321.~~$12,283.

~~These circumstances raise substantial doubt~~On August 1, 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with Petrichor Opportunities Fund I LP (the “Investor”) in connection with the issuance of up to $45,000 of senior secured floating rate convertible notes (the “Notes”), issuable in multiple tranches (the “Note Financing”). On August 19, 2022, the Company closed the initial tranche of $5,000 (the “First Closing Note”) which has an initial conversion price equal to $8.11 per share, which was calculated based on a 20% premium of the 5-day volume weighted average price of the Company’s common shares as traded on the Nasdaq Capital Market (the “VWAP”) immediately prior to the ~~ability~~announcement of the SPA. In connection with the first closing, the Company repaid in full its secured indebtedness with Bridge Bank in the amount of $5,000.

On September 23, 2022, the Company closed the second tranche of the Note Financing in the amount of $20,000 the “Second Closing Note”), which has an initial conversion price equal to $7.89 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to September 20, 2022, which was the date the Company obtained FDA approval of PEDMARK®.

Subsequent to the funding of the Second Closing Note, and before December 31, 2023, the Company may draw up to $20,000 of additional financing under the SPA, in one or more tranches of $10,000 upon mutual agreement of the Company and the Investor (the “Subsequent Closing Notes”). The Subsequent Closing Notes will be convertible at a price per share equal to ~~meet its obligations~~$7.89 per share, which price is calculated on the same basis as ~~they come due~~for the Second Closing Note.

A commitment fee of 2.0% of the Notes was payable under the SPA. Half of such fee was paid by the issuance on the first closing of warrants to purchase approximately 0.05 Fennec common shares (“First Closing Warrant”) and ~~accordingly,~~half was payable in cash or warrants of approximately 0.05 Fennec common shares (“Second Closing Warrant”), at the ~~use~~Company’s election, on the second closing. The warrants are exercisable at a price per share of ~~accounting principles applicable to~~$8.11 and will have a ~~going concern may not be appropriate.~~term of five years from the date of the grant. The Company ~~will need~~elected to ~~obtain additional~~have all the commitment fee of the Notes payable in warrants.

The Company believes current funds, which include funds from the First Closing Note and the Second Closing Note, provide sufficient funding for the Company to carry out its planned activities, including the continuation of commercialization efforts of PEDMARK^® in the ~~future~~United States and preparation for commercialization of PEDMARK^® outside of the United States, for at least the next twelve months.

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in order to finance the Company’s business strategy, operations and growth through the issuance of equity, debt or business combinations. If the Company fails to arrange for sufficient capital on a timely basis, the Company may be required to curtail its business activities until it can obtain adequate financing. However, as of September 30, 2017, we had cash and cash equivalents of $9,688 and believe that our cash resources will be sufficient to meet our cash requirements through and beyond current fiscal year.thousands, except per share information)

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

~~Significant Accounting Policies~~

2. Significant Accounting Policies

Basis of ~~presentation~~

Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the ~~Company's~~Company’s audited condensed consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the ~~Company's~~Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2022. The ~~Company's~~Company’s accounting policies are consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2022. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.

The results of operations for the three and nine months ended September 30, 2023, are not necessarily indicative of results to be expected for the full fiscal year.

Use of ~~estimates~~

Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the ~~interim condensed~~ consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include product sales discounts and allowances, allowance against trade receivables, measurement of stock-based compensation and estimates of the Company’s capital requirement over the next twelve months from the date of issuance of the consolidated financial statements. Actual results could differ from those estimates.

Segment and Geographic Information

InOperating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the ~~opinion~~chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment principally in the United States. As of ~~management, these unaudited interim condensed consolidated financial~~September 30, 2023, the Company had an operating lease in Ireland. This is the only asset located outside of the United States.

Stock-Based Compensation

Under the Company’s stock-based compensation programs, the Company periodically grants stock options and restricted stock units to employees, directors, and consultants. The fair value of each award is recognized in the Company’s statements ~~include all adjustments,~~of operations over the requisite service period for such award.

The Company uses the Black-Scholes option pricing model to value stock option awards without market conditions, which ~~are normal~~requires the Company to make certain assumptions regarding the expected volatility of its common stock price, the expected term of the option grants, the risk-free interest rate and ~~recurring in nature, necessary for~~ the ~~fair presentation~~dividend yield with respect to its common stock. The Company calculates volatility using its historical stock price data. Due to the lack of the Company’s ~~financial position at September 30, 2017 and~~own historical data, the Company elected to ~~state fairly~~use the ~~results~~“simplified” method for “plain vanilla” options to estimate the ~~periods presented. The most significant estimates utilized during the quarter ended September 30, 2017 included estimates necessary to value derivative instruments, disclosed in Note 4.~~

~~New accounting pronouncements~~

In February 2017, the FASB issued ASU No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05 is meant to clarify the scopeexpected term of the ~~original guidance within Subtopic 610-20 that was issued~~Company’s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the United States Treasury yield curve in ~~connection~~effect at the time of grant for instruments with ~~ASU 2014-09, as defined below, which provides guidance for recognizing gains and losses from~~a similar expected life. The Company utilizes a dividend yield of zero based on the transfer of nonfinancial assets in contracts with noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal year beginning December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. We are currently evaluating the impactfact that the ~~adoption~~Company has never paid cash dividends and, at present, has no intention to pay cash dividends.

Table of ~~ASU 2017-05 may have on our consolidated financial statements and disclosures.~~Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Inventory

~~In May 2017,~~Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the ~~Financial~~lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories mainly include third party manufacturing, logistics and distribution costs. The Company assesses the recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories. The manufacturing costs for PEDMARK^®prior to regulatory approval were not capitalized as inventory but were expensed as research and development costs. The Company expensed pre-launch inventory as it could not reasonably anticipate FDA approval of PEDMARK^®.

Revenue Recognition

Under Accounting Standards ~~Board~~Codification (“~~FASB”~~ASC”) ~~issued Accounting Standards Update 2017-09,~~~~Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting~~(“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance is effective for the Company as of the fourth quarter of its fiscal year ending December 31, 2018. Early adoption is permitted. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact of this updated standard, but does not believe this update will have a significant impact on its consolidated financial statements.

~~In May 2014, the FASB issued ASU 2014-9,~~606, Revenue from Contracts with Customers, ~~(Topic 606), to clarify~~ the ~~principles for recognizing revenue. This update provides a comprehensive new~~Company recognizes revenue ~~recognition model that requires revenue to be recognized in a manner to depict the transfer~~when its customers obtain control of promised goods or services, ~~to a customer at~~in an amount that reflects the consideration ~~expected~~which the Company determines it expects to ~~be received~~receive in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The newTo determine revenue ~~standard allows~~recognition for either full retrospective or modified retrospective application. The Company currently does not have any revenue and therefore does not expect this update will have a significant impact on its consolidated financial statements.

~~In February 2016, the FASB issued ASU 2016-02,~~~~Leases~~, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required byarrangements that the Company ~~until~~determines are within the ~~beginning~~scope of ~~fiscal 2019, although early adoption is permitted. The~~ASC 606, the Company ~~has not yet completed~~performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies its ~~assessment of the impact that adoption of this guidance will have on its financial statements.~~

~~In March 2016, the FASB issued ASU 2016-09,~~~~Improvements to Employee Share-Based Payment Accounting~~~~, which amends the accounting for share-based payment transactions. These changes, which are designed for simplification, involve several aspects~~performance obligation(s). As part of the accounting for ~~share-based transactions,~~these arrangements, the Company must make significant judgments, including identifying performance obligations in the ~~income tax consequences, classification~~contract and estimating the amount of ~~awards as either equity~~ variable consideration to include in the transaction price.

Net Product Revenue

On September 20, 2022, the FDA approved PEDMARK^® in the United States to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. PEDMARK^® became commercially available in the United States on October 17, 2022. PEDMARK^® is the Company’s first commercial product. The Company sells its product through the following specialty distributors: Amerisource Specialty Distribution (“ASD”), McKesson Plasma and Biologics, McKesson Specialty, and Cardinal Health Specialty (collectively the “Customers” and each a “Customer”). Further, the Company sells directly to other customers without the use of specialty distributors. These Customers subsequently resell the Company’s products to health care providers and patients. In addition to distribution agreements with Customers, the Company enters arrangements with health care providers and payors that provide for government-mandated and/or ~~liabilities,~~privately-negotiated rebates, chargebacks, and ~~classification~~discounts with respect to the purchase of the Company’s products. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon delivery to the Customer. The amount of revenue recognized is net of these discounts in an amount equal to the cash expected to be collected.

Product Sales Discounts and Allowances

The Company records revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the sales of its products. These reserves are based on the ~~statement~~amounts to be claimed on the related sales and are classified as a contra-asset or a current liability. Where appropriate, these estimates take into consideration a range of ~~cash flows.~~possible outcomes that are probability-weighted for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, forecasted Customer buying and payment patterns, and the Company’s historical experience that will develop over time as PEDMARK^® is the Company’s first commercial product. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of its contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.

Chargebacks: Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist of Public Health Service institutions and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by its contracted customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales by the specialty distributor to its contracted customers.

Discounts for Prompt Payment: Customers receive a discount of 0.65% for prompt payment. The Company ~~adopted this ASU~~expects its Customers will earn 100% of their prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized.

Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. The Company’s estimates for the expected utilization of rebates are based on Customer and payor data received from the specialty distributors and historical utilization rates that will develop over time, as PEDMARK^® is the Company’s first commercial product. Rebates are generally invoiced by the payor and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s shipments to the Customers, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenues in the period of adjustment.

Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the third party that administers the copay program. If actual program redemption varies from estimates, the Company may need to adjust its accruals, which would affect net product revenues in the period of adjustment.

Other Customer Credits: The Company pays fees to certain of its Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to its Customers, the Company classifies these payments in selling and marketing, general and administrative expenses in its Condensed Consolidated Statements of Operations.

The following table summarizes net product revenues for PEDMARK^® in the United States and abroad earned during the three and nine months ended September 30, 2023 and 2022, respectively:


	Three Months Ended				Nine Months Ended
		September 30,		September 30,		September 30,		September 30,
In thousands		2023		2022		2023		2022
Product revenues:
Gross product revenues	$	6,919	$	—	$	12,525	$	—
Discounts and allowances		(404)		—		(1,008)		—
Net product revenues	$	6,515	$	—	$	11,517	$	—

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

The following table summarizes the percentage of total product revenues for PEDMARK^® in the United States and abroad by Customers who individually accounted for 10% or more of total product revenues earned in the three and nine months ended September 30, 2023, and 2022, respectively:


	Three Months Ended				Nine Months Ended
	September 30,		September 30,			September 30,		September 30,
Specialty Distributors	2023		2022			2023		2022
ASD	16	%	—	%		24	%	—
McKesson	19		—			16		—
Subtotal-Specialty Distributors	35		—			40		—
Direct Customers	65		—			60		—
	100	%	—	%		100	%	—

The activities and ending allowance balances for each significant category of discounts and allowances for PEDMARK^® (which constitute variable consideration) for the nine months ended September 30, 2023, was as follows:



	Chargebacks,		Rebates, Customer
	Discounts for		Fees/Credits
	Prompt pay and		and Co-Pay
In thousands	Other allowances		Assistance		Totals
Balance at December 31, 2022	$	71	$	163	$	234
Provision related to sales made in:
Current period		116		117		233
Prior periods		—		—		—
Payments and customer credits issued		(31)		(66)		(97)
Balance at March 31, 2023	$	156	$	214	$	370
Provision related to sales made in:		246		148		394
Current period		—		—		—
Prior periods		—		—		—
Payments and customer credits issued		(193)		(124)		(317)
Balance at June 30, 2023	$	209	$	238	$	447
Provision related to sales made in:
Current period		334		180		514
Prior periods		—		—		—
Payments and customer credits issued		(307)		(71)		(378)
Balance at September 30, 2023	$	236	$	347	$	583

The allowances for chargebacks, fees due to Customers, rebates and discounts for prompt payment are recorded as a contra-asset to accounts receivable, while Medicaid rebates and return allowances are in accrued liabilities in the accompanying Condensed Consolidated BalanceSheets.

Trade Receivables

The Company records gross tradereceivables at the time of product sale to its Customers. Amounts estimated for the associatedchargebacks,cashdiscountsforpromptpaymentandanyallowancesforcreditlosses are booked as a reserve against accounts receivable and reduction of revenue.TheCompany determines its allowance methodology by pooling receivable balances at the Customer level. The Company considers various factors, including loss history, individual credit risk associated to each Customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

characteristics of such a Customer. The Customers are mainly specialty distributors, and accordingly, the Company considers the risk of potential credit losses to be low. It is the policy of the Company to reserve 1% of its net sales to non-specialty distributors, as such the Company had an immaterial balance in allowance for doubtful accounts as of ~~January 1, 2017. There has been no impact~~September 30, 2023.

Cost of Products Sold

Cost of products sold is related to the ~~financial statements~~

Company's product revenues for PEDMARK^® and consists primarily of product production costs associated with finished goods inventory and royalties (1% of net sales) the Company is required to pay to Oregon Health & Science University (“OHSU”) on all net sales of PEDMARK^®. The cost of products sold also consists of shipping and other third party logistics and distribution costs for PEDMARK^®. The Company considered regulatory approval of PEDMARK^® to be uncertain and product manufactured prior to regulatory approval could not have been sold unless regulatory approval was obtained. As such, the manufacturing costs for PEDMARK^® incurred prior to regulatory approval were not capitalized as inventory but were expensed as research and development costs. After FDA approval in September 2022, the Company had various lots of PEDMARK^® in various stages of production in connection with the product launch. As of September 30, 2023, the Company capitalized approximately $1.8 million of costs as inventory on the Condensed Consolidated Balance Sheet. Of the items capitalized, $0.1 million was capitalized as raw materials, $0.9 million was capitalized as work in process, $0.8 million was capitalized into finished goods, with $0.6 million being reclassified to cost of products sold.

Cash and ~~cash equivalents~~

Cash Equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At September 30, ~~2017,~~2023, the Company had ~~$9,688~~$12,399 in cash, savings and money market accounts ($~~3,926~~23,774 at December 31, ~~2016)~~2022). At September 30, ~~2017,~~2023, the Company held ~~$440~~$2,007 in cash of which ~~$282~~$488 (as presented in USU.S. dollars) was in Canadian dollars ($5134 at December 31, ~~2016~~2022 as presented in USU.S. dollars). At September 30, ~~2017,~~2023, the Company held ~~$9,248~~$10,392 in money market investments. Money market investments typically have minimal risks. ~~The~~While the Company has not experienced any loss or write-down of its money market investments, ~~since inception.~~the amounts it holds in money market accounts are substantially above the $250 amount insured by the FDIC and may lose value.

~~Earnings per Share~~

Financial Instruments

~~Earnings~~Financial instruments recognized on the balance sheets at September 30, 2023 and December 31, 2022 consist of cash and cash equivalents, accounts receivable, accounts payable and term loans, the carrying values of which approximate fair value due to their relatively short time to maturity or interest rates that approximate market interest rates. The Company does not hold or issue financial instruments for trading.

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per ~~common~~ share information)

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. Until the company is ~~presented~~cash flow positive from operations, the Company has chosen to avoid investments of a trading or speculative nature.

Research and Development Costs and Investment Tax Credits

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under ~~two formats: basic earnings~~contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, andaccountsreceivable.TheCompanymaintainsdepositsinhighly-rated,federally-insuredfinancialinstitutionsinexcessoffederallyinsuredlimits.TheCompany’sinvestmentstrategyisfocusedoncapitalpreservation.TheCompanyinvestsininstrumentsthatmeetthehighcreditqualitystandardsoutlinedintheCompany’sinvestmentpolicy.Thispolicyalsolimitstheamountofcreditexposuretoanyoneissueortypeofinstrument.

The Company’s trade receivables include amounts billed to Customers for product sales of PEDMARK^®. The Customers are a limited group ofspecialtydistributors and select customers abroad, with substantial financial resources,andaccordingly,theCompanyconsiderstheriskofpotentialcreditlossestobelow.

Income Taxes

The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of September 30, 2023, we maintained a full valuation allowance against our deferred tax assets.

The provisions of the FASB ASC 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.

Foreign Currency Transactions

The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency transactions are included in results of operations.

New Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” This ASU replaces the incurred loss impairment methodology in current US GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for the Company for fiscal years

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per ~~common~~ share information)

beginning after December 15, 2022, as the Company is a smaller reporting company as defined in Item 10(f)(1) of Regulation S-K. We adopted ASU 2016-13 on January 1, 2023. Based on the composition of the Company’s accounts receivable, the adoption of this standard did not have a material impact on the Company’s consolidated financial statements or disclosures. Specifically, the Company’s estimate of expected credit losses as of September 30, 2023, using its expected credit loss evaluation process, resulted in no adjustments to the provision for credit losses and ~~diluted earnings~~no cumulative effect adjustment to accumulated deficit on the adoption date of the standard.

In July 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-03 to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, “Presentation of Financial Statements (Topic 205), Income Statement-Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation-Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280-General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” ASU 2023-03 amends the ASC for SEC updates pursuant to SEC Staff Accounting Bulletin No. 120; SEC Staff Announcement at the March 24, 2022 Emerging Issues Task Force (“EITF”) Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.

In October 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-06 to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect SEC Release No. 33-10532, Disclosure Update and Simplification. ASU 2023-06 amends disclosure guidance over an entity’s accounting policy related to derivative instruments, material prior period adjustments upon a change in a reporting entity, earnings-per-share, encumbered assets, unused lines of credit and unfunded commitments, and liquidation preferences of preferred stock. The amendments are effective prospectively on the date each individual amendment is effectively removed from Regulation S-X or Regulation S-K.

3. Loss Per Share

Basic net loss per ~~common share. Basic earnings per common~~ share is computed by dividing net ~~income attributable to common shareholders~~loss by the weighted average number of common shares outstanding during the ~~period.~~year. Diluted ~~earnings~~net loss per ~~common~~ share is computed ~~by dividing net income by~~using the same method, except the weighted average number of common shares outstanding ~~during the period, plus the potentially dilutive impact of common stock equivalents (i.e.~~includes convertible debentures, stock options and ~~warrants). Dilutive common share equivalents consist~~warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, warrants to purchase 0.2 million of ~~the incremental~~our common shares ~~issuable upon exercise~~and options to purchase 5.0 million of ~~stock~~our common shares at September 30, 2023, were not included in loss per share. Such instruments would have an antidilutive effect. During the same period in 2022, warrants to purchase 0.04 million of our common shares and options ~~and warrants. The following table sets forth~~to purchase 4.3 million common shares were excluded from the computation of ~~basic and diluted net~~ loss per ~~share:~~share as their inclusion would have been anti dilutive

~~Fennec Pharmaceuticals Inc.~~

~~Notes to the Unaudited Interim Condensed Consolidated Financial Statements~~

~~(U.S. dollars and shares in thousands, except per share information)~~

Three Months Ended
September 30, Nine Months Ended
September 30,
2017 2016 2017 2016
Numerator:
Net (loss) $ (2,352 ) $ (502 ) $ (4,756 ) $ (1,646 )

Denominator:
Weighted-average common shares, basic 15,740 13,643 14,533 12,469

Dilutive effect of stock options - - - -
Dilutive effect of warrants - - - -
Incremental dilutive shares - - - -

Weighted-average common shares, dilutive 15,740 13,643 14,533 12,469

Net (loss) per share, basic and diluted $ (0.15 ) $ (0.04 ) $ (0.32 ) $ (0.13 )

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

Three Months Ended
September 30, Nine Months Ended
September 30,
2017 2016 2017 2016
Options to purchase common stock 2,361 2,422 2,361 2,422
Warrants to purchase common stock 1,362 1,749 1,362 1,749


	Nine Months Ended September 30,
	2023	2022
Options to purchase common shares	5,005	4,466
Warrants to purchase common shares	150	150

~~Derivative Instruments~~

The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' equity.

~~The Company's derivative instruments include options to purchase 39 common shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:~~

~~Contractor options to purchase 20 common shares exercisable at CAD$1.89 per whole common share that expire on November 19, 2017;~~

~~Contractor options to purchase 17 common shares exercisable at CAD$1.62 per whole common share that expire on April 4, 2018;~~

~~Contractor options to purchase 2 common shares exercisable at CAD$2.43 per whole common share that expire on May 18, 2018.~~

These options have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date until they are exercised, forfeited or expire. Any change in value between reporting periods will be recorded as unrealized gain/(loss). The fair value of these warrants and options is estimated using the Black-Scholes option-pricing model using the following assumptions for the current balance sheet date: expected dividend 0%; risk-free interest rate 0.76%; expected volatility between 97% - 100%; and an expected life between 0.5 – 0.63 years.

Comparative data related to gain/(loss) recorded on re-measurement of the derivative liability for the three and nine month period ended September 30, 2017 and 2016 are summarized in the table below. There is no cash flow impact for these derivatives until the warrants and/or options are exercised. If these warrants or options are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

During the fiscal years ended December 31, 2011 and 2010, the Company issued 36 and 29, respectively, options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry, exercise or forfeiture.

~~Fennec Pharmaceuticals Inc.~~

~~Notes to the Unaudited Interim Condensed Consolidated Financial Statements~~

~~(U.S. dollars and shares in thousands, except per share information)~~

Three Months Ended
September 30, Nine Months Ended
September 30,
Gain/(Loss) on Derivative Instruments 2017 2016 2017 2016
Derivatives expired March 29, 2016 $ - $ - $ - $ 41
Options to contractors (183 ) 19 (340 ) 4
Gain/(loss) on Derivative Instruments $ (183 ) $ 19 $ (340 ) $ 45

~~The table below summarizes Canadian dollar denominated contractor option activity, during the interim period:~~

Contractor Options in $CAD Three Month Period Nine Month Period Weighted-Average
Options in Thousands Ending September 30, 2017 Exercise Price
Opening balance 39 40 $ 1.81
Exercised - (1 ) 2.05
Forfeited - - -
Expired - - -
Ending balance 39 39 $ 1.80

Canadian dollar denominated options issued to contractors vest immediately and are treated as derivative liabilities. In the case a derivative option is exercised, upon the exercise date, the Company extinguishes the derivative liability, records the cash received and the shares issued into common stock and additional paid in capital accordingly. During the three and nine month period ended September 30, 2017, there was an exercise of 1 Canadian denominated option being treated as a derivative liability. This exercise resulted in $2 gross proceeds to the Company.

~~NASDAQ Listing~~

On September 13, 2017, the Company began trading its common shares on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “FENC”. Prior to the Nasdaq listing, the Company had been trading on the OTCB Marketplace (the “OTCQB”) since January of 2009 under the ticker symbol “FENCF”.

~~Stockholders' Equity~~

4. Stockholders’ Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of common shares, of no par ~~common stock.~~value per share.

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Warrants to Purchase Common Stock

During the three and nine months ended September 30, 2023 and 2022, there were no warrants issued or exercised. The ~~Company~~company has 150 outstanding warrants ~~outstanding to purchase common stock priced in U.S. dollars with~~have a weighted average ~~price~~life of ~~$1.55~~4.30 years, and a weighted average ~~remaining life~~strike price of ~~1.15 years. During the quarter ended~~$7.79, on September 30, ~~2017, there were 21 warrants exercised resulting in gross proceeds to the Company of $31.~~2023.

~~Warrant~~	~~Common Shares Issuable Upon Exercise of~~		~~Exercise Price~~
~~Description~~	~~Outstanding Warrants at September 30, 2017~~		~~$USD~~	~~Expiration Date~~
~~Investor warrants~~		~~1,312~~	~~$1.50 USD~~	~~November 22, 2018~~
~~Investor warrants~~		50	~~$3.00 USD~~	~~February 2, 2019~~
~~Total~~		~~1,362~~

~~Stock option plan~~

Equity Incentive Plan

The Compensation Committee of the Board of Directors administers the Company’s ~~stock option plan.~~equity incentive plan (the “Plan”). The Compensation Committee designates eligible participants to be included under the ~~plan~~Plan and approves the number of ~~options~~equity instruments to be granted from time to time under the ~~plan.~~Plan. Currently, the maximum number of equity instruments issuable under the Plan, together with the Company’s prior stock option ~~shares issuable~~plan, is twenty-five percent (25%) of the total number of issued and outstanding ~~shares of~~ common ~~stock.~~shares. Based upon the current shares outstanding, a maximum of ~~3,964 options~~6,658 shares of common stock are authorized for issuance pursuant to stock options or other equity awards granted under the ~~plan.~~Plan. For all options issued under the ~~plan,~~Plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ~~seven~~ten years from the date of grant. The ~~stock option plan~~Plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense from equity awards for the three and nine month periods ended September 30, ~~2017~~2023 and ~~2016.~~2022.

	Three Months Ended September 30,				Nine months Ended September 30,
	2017		2016		2017		2016

									Three Months Ended				Nine Months Ended
									September 30,		September 30,		September 30,		September 30,
									2023		2022		2023		2022
Contractor options expense recognized	$	210	$	9	$	552	$	9	$	—	$	34	$	—	$	103
Employee options expense recognized		907		41		1,409		152		865		1,853		4,497		3,260
Total option expense recognized	$	1,117	$	50	$	1,961	$	161	$	865	$	1,887	$	4,497	$	3,363

~~Fennec Pharmaceuticals Inc.~~

~~Notes to the Unaudited Interim Condensed Consolidated Financial Statements~~

~~(U.S. dollars and shares in thousands, except per share information)~~

Stock ~~option activity~~

~~The following is a summary of option activity for each of the quarterly periods in fiscal year 2017 for stock options denominated in US dollars:~~

Number of Weighted-Average
US Denominated Options Options (thousands) Exercise Price $USD
Outstanding December 31, 2016 1,428 1.93
Granted - -
Exercised - -
Forfeited - -
Outstanding at March 31, 2017 1,428 1.93
Granted 300 4.84
Exercised (50 ) 0.64
Forfeited - -
Outstanding at June 30, 2017 1,678 2.48
Granted 21 6.72
Exercised (72 ) 1.69
Forfeited (3 ) 2.79
Outstanding at September 30, 2017 1,624 2.57

During the three and nine month periods ended September 30, 2017, US denominated option exercises provided gross proceeds of $121 and $153, respectively. US denominated option exercises during the three and nine month periods ended September 30, 2017, resulted in the issuance of 72 and 122 common shares, respectively. Of the 1,624 options granted and outstanding at September 30, 2017, 1,348 are fully vested and exercisable.

Option Activity

The following is a summary of option activity for the three and nine months ended September 30, ~~2017~~2023 for stock options denominated in ~~Canadian dollars:~~U.S. dollars.

	Number of			Weighted-Average
Canadian Denominated Options	Options (thousands)			Exercise Price $CAD
Outstanding December 31, 2016		999			2.38

						Number of	Weighted-Average
Options						Options (thousands)	Exercise Price $USD
Outstanding at December 31, 2022						4,539	$	5.13
Granted						580		8.12
Exercised		-			-	(49)		4.36
Forfeited		-			-	(38)		6.98
Outstanding at March 31, 2017		999			2.38
Outstanding at March 31, 2023						5,032		5.43
Granted						125		8.80
Exercised		(36	)		2.42	(95)		5.60
Forfeited		-			-	(175)		7.51
Outstanding at June 30, 2017		963			2.37
Outstanding at June 30, 2023						4,887	$	5.77
Granted						370		7.88
Exercised		(135	)		2.43	(92)		2.34
Forfeited		(91	)		2.40	(160)		7.35
Outstanding at September 30, 2017		737			2.36
Outstanding at September 30, 2023						5,005	$	5.94

Table of Contents

~~For~~Fennec Pharmaceuticals Inc.

Notes to the ~~nine months ended~~Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Of the 5,005 U.S. denominated options granted and outstanding at September 30, 2017, there was no issuance activity related to Canadian dollar denominated options. During the three months ended September 30, 2017, there were exercises of 135 Canadian denominated options which resulted in gross proceeds of CAD$329 ($261 as presented in US dollars). During the nine months ended September 30, 2017, there were exercises of 171 Canadian denominated options (1 treated as a derivative, 170 as non-derivative). These exercises resulted in gross proceeds of CAD$416 ($326 as presented in US dollars). During the same three2023, 3,932 are fully vested and ~~nine month periods ended 2016, Canadian denominated option activity consisted of 324 forfeitures. As of September 30, 2017, all outstanding options denominated in Canadian dollars were fully vested.~~

~~Valuation assumptions~~

exercisable.

The value of options ~~granted were~~issued was estimated using the Black-Scholes option pricing model using the ~~following~~ assumptions in the table ~~below:~~below. The expected volatility was determined using historical volatility of our ~~stock~~common shares based on the ~~contractual life~~expected term of the award. ~~There were 21 options issued during~~


		Valuation
		Assumptions
Black-Scholes Model Assumptions		September 30, 2023
Expected dividend		0.00%
Risk free rate		3.56 - 5.12%
Expected volatility		49 - 77%
Expected life		1.5 - 6.0 years

Restricted Share UnitsActivity

The Plan allows for the issuance of restricted share units (“RSUs”). The following is a summary of RSU activity for the three and nine months ended September 30, ~~2017, (285 for~~2023. During the ~~same period in 2016). Assumptions for~~three and nine months ended September 30, 2023, there were 32 and 36 RSU’s released from restriction, respectively. During the ~~valuation~~three and nine months ended September 30, 2023, there were 84 and 101 RSUs forfeited by departing employees. RSUs vesting vary from one to three years.


		Number of
		Restricted Share
RSUs Current Year		Units (thousands)
Outstanding at December 31, 2022		35
Awarded		264
Released		(1)
Outstanding at March 31, 2023		298
Awarded		98
Released		(3)
Forfeited		(17)
Outstanding at June 30, 2023		376
Awarded		—
Released		(32)
Forfeited		(84)
Outstanding at September 30, 2023		260

The value of RSUs issued was estimated using the share price on the date of the ~~option grants are described in~~award multiplied by the ~~table below:~~

~~Fennec Pharmaceuticals Inc.~~

~~Notes to the Unaudited Interim Condensed Consolidated Financial Statements~~

~~(U.S. dollars and shares in thousands, except per share information)~~

Three Months Ended
September 30,
Black-Scholes Model Assumptions 2017 2016
Expected dividend 0.00 % 0.00 %
Risk free rate 2.04 % 1.27 %
Expected volatility 162 % 136 %
Expected life 7 years 7 years

~~Shareholder rights plan~~

On June 27, 2017, the Company’s shareholders approved a Shareholder Rights Plan Agreement (the "Rights Plan") for the Company. The Rights Plan is to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or other acquisition of control of the Corporation. The Rights Plan is designed to require any potential transaction that will result in a person owning, in the aggregate, 20% or more of the outstanding Common Shares to be structured as a formal take-over bid that satisfies certain minimum requirements relating primarily to the manner in which the bid must be made, the minimum number of ~~days the bid must remain open, and the minimum number of~~common shares ~~that must be acquired under the bid.~~granted.

~~Fair Value Measurements~~

5. Fair Value Measurements

The Company has adopted ASC 820, the Fair Value Measurements and Disclosure Topic of the ~~FASB in 2011.~~FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable ~~market based~~market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Fair Value Measurement at September 30, 2017
Assets/Liabilities Measured at
Fair Value on a Recurring Basis Quoted Price in
Active Markets for
Identical
Instruments Significant Other
Observable Inputs Significant
Unobservable
Inputs
Level 1 Level 2 Level 3 Total
Assets
Cash and cash equivalents $ 440 ⁽¹⁾ $ 9,248 $ - $ 9,688
Liabilities
Derivative liabilities - - 373 373


	Fair Value Measurement at September 30, 2023 and December 31, 2022
	(in thousands)
	Quoted Price in Active
	Market for Identical						Significant Other				Significant
	Instruments						Observable Inputs				Unobservable Inputs
	Level 1						Level 2				Level 3					Total
	2023				2022			2023		2022		2023		2022		2023		2022
Assets
Cash and cash equivalents	$	2,007	⁽¹⁾	$	307	⁽¹⁾	$	10,392	$	23,467	$	—	$	—	$	12,399	$	23,774
Processa common shares	$	13	⁽²⁾	$	56	⁽²⁾	$	—	$	—	$	—	$	—	$	13	$	56

(1)

~~(1)~~

The Company held ~~$440~~approximately $2,007 in cash as of September 30, 2023, of which approximately $488 was in Canadian funds (translated into U.S. dollars). As of December 31, 2022, the Company held approximately $307 in cash of which ~~$282 (as presented in US dollars)~~approximately $33 was in Canadian ~~funds.~~funds (translated into U.S. dollars).

(2)	The Company holds 51 unrestricted common shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), which it received as part of a royalty arrangement in 2020.

~~The Company's financial instruments include cash~~6. Commitments and ~~cash equivalents and derivatives. The derivative liabilities include options issued to contractors in a currency other than the functional currency of the Company.~~

~~Commitments and Contingencies~~

Contingencies

Oregon Health & Science University Agreement

On February 20, 2013, ~~Fennec~~we entered into ~~a new~~an exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to ~~STS~~thiol-based compounds, including PEDMARK^®, and ~~its~~their use ~~for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy,~~ in ~~humans~~oncology (the ~~"New OHSU Agreement"~~“OHSU Agreement”).

~~The term~~OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the ~~New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents~~ licensed to the Company, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe, Canada and Australia in 2021 and are currently pending in the United States and Japan. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

technology.

On May 18, 2015, ~~Fennec~~we negotiated an amendment ("(“Amendment 1"1”) to the OHSU Agreement, which expands Fennec’s exclusive license ~~agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 or New OHSU Agreement~~ to include the use of N-acetylcysteine as a standalone therapy and/or in combination with ~~Sodium Thiosulfate ("STS")~~sodium thiosulfate for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments ~~entered~~ in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product.

The term of ~~Amendment 1 under~~ the OHSU Agreement as amended by Amendment 1 expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. PEDMARK^® is currently protected by methods of use patent that the Company exclusively licensed from OHSU that expire in the United States in 2038. The OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the OHSU Agreement.

Securities Class Action Suit

Chapman v. Fennec Pharmaceuticals Inc., et al.

On September 3, 2020, plaintiff Jim Chapman filed a putative federal securities class action lawsuit against the Company, our Chief Executive Officer, Rostislav Raykov, and Chief Financial Officer, Robert Andrade, in the United States District

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Court for the Middle District of North Carolina, captioned Chapman v. Fennec Pharmaceuticals Inc., et al., Case No. 1:20-cv-00812. The complaint alleged that prior to our August 10, 2020 receipt of a CRL from the FDA concerning our NDA for PEDMARK^®, defendants made materially false or misleading statements and failed to disclose material facts about our third-party PEDMARK^® product manufacturing facility and the impact the facility would have on regulatory approval for PEDMARK^®. On December 3, 2020, the court appointed a lead plaintiff to represent the putative class. On February 1, 2021, the lead plaintiff filed an amended complaint. The amended complaint added members of our Board of Directors as defendants, asserted a putative class period from December 20, 2018 through August 10, 2020, made allegations similar to those in the original complaint, claimed that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, and sought an unspecified amount of compensatory damages and attorneys’ fees and costs.

On March 3, 2021, defendants filed a motion to dismiss the amended complaint. On April 2, 2021, lead plaintiff filed an opposition to the motion to dismiss. On April 16, 2021, defendants filed a reply in support of the motion to dismiss, and on December 16, 2021, the Magistrate Judge entered an order recommending that defendants’ motion to dismiss be granted in its entirety. On January 24, 2022, lead plaintiff filed objections to the Magistrate Judge’s recommendation, and defendants filed their response on February 3, 2022. On March 2, 2022, the U.S. District Court Judge adopted the Magistrate Judge’s order and recommendation and entered an order and judgment dismissing the amended complaint with prejudice.

On March 30, 2022, lead plaintiff filed a motion for post judgment relief, seeking leave to file a second amended complaint. In his proposed second amended complaint, lead plaintiff sought to add allegations stemming from the receipt of a second CRL following our resubmission of our NDA for PEDMARK^®, which we received on November 29, 2021, among other things. Defendants filed an opposition to plaintiff’s motion for post judgment relief on April 20, 2022. On May 4, 2022, lead plaintiff submitted a reply in support of his motion. On September 27, 2022, defendants filed a request for judicial notice regarding the FDA’s press release announcing that it has approved PEDMARK^®. On October 18, 2022, lead plaintiff filed his opposition to request for judicial notice. On October 21, 2022, defendants filed a reply in support of the request for judicial notice. On February 15, 2023, the Magistrate Judge recommended the motion for post judgment relief be denied. Lead plaintiff filed no timely objection to the recommendation, and on March 2, 2023, the U.S. District Court Judge issued an order adopting the Magistrate Judge’s recommendation, denying the motion for post judgment relief, and entering judgment for defendants. Lead plaintiff had until April 3, 2023 to file a notice of appeal and did not file a notice of appeal. The case is now closed.

Fisher v. Fennec Pharmaceuticals Inc. et al.

On February 9, 2022, plaintiff Jeffrey D. Fisher filed a putative federal securities class action lawsuit against the Company and our CEO and CFO in the United States District Court for the Middle District of North Carolina, captioned Fisher v. Fennec Pharmaceuticals Inc., et al., Case No. 1:22-cv-00115. The complaint asserted a putative class period from May 28, 2021 through November 28, 2021, and alleged that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by making materially false and misleading statements or omissions regarding the status of our third-party PEDMARK^® product manufacturing facility, the facility’s compliance with cGMP, and the impact its status and compliance would have on regulatory approval for PEDMARK^® in the period leading up to the Company’s November 29, 2021 receipt of a CRL for a subsequent NDA for PEDMARK^®. The complaint sought an unspecified amount of damages and attorneys’ fees and costs. On April 11, 2022, plaintiff Jeffrey D. Fisher filed a motion to be appointed lead plaintiff and represent the putative class and on May 9, 2022, the court appointed him as lead plaintiff.

On June 23, 2022, lead plaintiff filed an amended complaint. The amended complaint asserted the same putative class period from May 28, 2021 through November 28, 2021, was brought against the same defendants and made allegations similar to those in the original complaint. On August 5, 2022, defendants filed a motion to dismiss the amended complaint. On August 26, 2022, lead plaintiff filed an opposition to the motion to dismiss. On September 9, 2022, defendants filed a reply in support of the motion to dismiss.

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

On September 27, 2022, defendants filed a request for judicial notice regarding the FDA’s press release announcing that it approved PEDMARK^®. On September 30, 2022, lead plaintiff filed an opposition to the request for judicial notice. On October 6, 2022, defendants filed a reply in support of the request for judicial notice. On October 12, 2022, the U.S. District Court Judge issued a memorandum opinion and order dismissing the amended complaint in its entirety and with prejudice, and on October 14, 2022, entered judgment. Lead plaintiff had until November 14, 2022 to file a notice of appeal and did not file a notice of appeal. The case is now closed.

Hope Medical Enterprises, Inc. Inter Partes Review Challenges

On October 29, 2021, Hope Medical Enterprises, Inc. (“Hope”) filed a Petition for inter partes review (IPR2022-00123) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO to invalidate U.S. Patent No. 10,596,190 (the “‘190 Patent”), which is exclusively in-licensed from Oregon Health & Science University (“OHSU”) and relates to a method of using PEDMARK^®. The ‘190 Patent was issued on March 24, 2020. On December 5, 2022, a Fennec filed a Motion to Amend the single claim of the ‘190 Patent focing on the treatment of medulloblastoma. On April 18, 2023, the PTAB invalidated the only claim of the‘190 Patent. The final written decision became effective June 20, 2023. The ‘190 Patent was previously listed in the United States Approved Drug Products with Therapeutic Equivalence Evaluations (also known as the “Orange Book”). In light of PTAB’s final written decision on the invalidity of the ‘190 Patent, we requested that the FDA remove the ’190 Patent from the Orange Book. Two United States patent applications claiming priority through the ‘190 Patent remain pending at the United States Patent and Trademark Office (“USPTO”).

On October 29, 2021, Hope Medical Enterprises, Inc. (“Hope”) filed a Petition for inter partes review (IPR2022-00125) to invalidate our wholly owned U.S. Patent No. 10,792,363 (the “’363 Patent”), which relates to an anhydrous form of STS and its method of manufacture, which is the active pharmaceutical ingredient in the PEDMARK^® product. The ‘363 Patent was issued October 6, 2020. In May 2022, the PTAB granted Hope’s Petition to Institute the IPR against the ‘363 patent. During the ‘363 IPR, we disclaimed the patent claims directed to the anhydrous morphic form of STS and continued with claims directed to its method of manufacture. Because the remaining claims in the ‘363 patent are directed to a method of manufacture, the ‘363 patent is not eligible for listing in the Orange Book. In September 2023, the PTAB issued a Final Written Decision in favor of Fennec and upholding the amended claim. Hope has until November 3, 2023 to request that PTAB reconsider the Final Written Decision, or alternatively, file an appeal of the Final Written Decision with the Court of Appeals for the Federal Circuit. If no further actions are taken, the ‘363 Patent as amended will remain in force.

The USPTO has now granted three additional U.S. patents that cover the PEDMARK^® formulation, each of which have been listed in the U.S. FDA’s “Orange Book” (U.S. Patent No. 11,291,728 (issued April 5, 2022), U.S. Patent No. 11,510,984 (issued November 29, 2022), and U.S. Patent No. 11,617,794 (issued April 4, 2023)), and additional United States patent applications from this family remain pending at the USPTO. We plan to vigorously defend our intellectual property rights to PEDMARK^®. An invalidation of our patents covering PEDMARK^® could have a material adverse effect on our ability to protect our rights in PEDMARK^® beyond periods of marketing exclusivity for PEDMARK^® in the United States under Orphan Drug Designation.

CIPLA ANDA Litigation

On December 1, 2022, we received a letter dated November 30, 2022, notifying us that CIPLA Ltd. and CIPLA USA (“CIPLA”) submitted to the FDA an ANDA (ANDA No. 218028) for a generic version of PEDMARK^® (sodium thiosulfate solution) that contains Paragraph IV Certifications on two of our patents covering PEDMARK^®: the OHSU licensed ‘190 Patent, expiration date January 2038; and our US 11,291,728 Patent (the “’728 Patent”), expiration date July 2039. On January 6, 2023, we received a letter dated January 5, 2023, notifying us that CIPLA submitted to the FDA a Paragraph IV Certification on our newly issued US 11,510,984 Patent (the “’984 Patent”). These patents are listed in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for PEDMARK^®. The certifications allege these patents are invalid or will not be infringed by the manufacture, use, or sale of CIPLA’s sodium thiosulfate solution.

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

Under the Food and Drug Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, after receipt of a valid Paragraph IV notice, the Company may bring a patent infringement suit in a federal district court against CIPLA within 45 days from the receipt of the Notice Letter and if such a suit is commenced within the 45-day period, the Company is entitled to a 30 month stay on the FDA’s ability to give final approval to any proposed products that reference PEDMARK^®. In addition to the 30-month stay, because we have received Orphan Drug Exclusivity, the FDA may not approve CIPLA’s ANDA for at least 7 years from PEDMARK^®’s FDA approval date of September 20, 2022.

On January 10, 2023, we filed suit against the CIPLA entities in the United States District Court for the District of New Jersey (Case No. 2:23-cv-00123), for infringement of the ‘190 Patent, the ‘728 Patent, and the ‘984 Patent. On April 20, 2023, we filed an Amended Complaint to assert infringement of the ‘728 patent and the ‘984 Patent. On April 4, 2023, we were granted US 11,617,793 Patent (the “’793 Patent”) covering the formulation of the PEDMARK^® product, which was listed in the Orange Book on or around April 17, 2023, and has an expiration date of July 2039. On May 11, 2023, we received written notice of CIPLA’s Paragraph IV Certification as to the ’793 Patent, which was dated May 10, 2023, along with an enclosed statement of alleged factual and legal bases for stating that the ’793 Patent is invalid, unenforceable, and/or will not be infringed by CIPLA’s ANDA Product. On July 27, 2023, we filed a Second Amended Complaint to assert the ‘793 Patent. The suit is ongoing.

PEDMARQSI^TM (EU Brand name for PEDMARK^®) received European Commission approval in June 2023 and was granted 10 years of market exclusivity in Europe under Pediatric Use (“PUMA”).

Executive Severance

In the event of ~~his~~Mr. Raykov's termination with usthe Company other than for cause, the Company will be obligated to pay ~~its Chief Executive Officer, Rostislav Raykov,~~him a one-time severance ~~compensation~~ payment equal to 12twelve months of salary (currently ~~$275)~~$585). ~~Further,~~In the event of Mr. Andrade’s termination with the Company other than for cause, the Company will be obligated to pay ~~Chief Financial Officer, Robert Andrade,~~him a one-time severance ~~compensation~~payment equal to ~~six-months~~six months of salary (currently ~~$100)~~$212).

Leases

The Company has an operating lease in Research Triangle Park, North ~~Carolina.~~Carolina utilizing a small space within a commercial building. The operating lease has payments of $0.4 per month with no scheduled increases. This operating lease is terminable with 30 days’ notice and has no penalties or contingent payments due.

On January 23, 2020, the Company entered into an Office Service Agreement (the “Office Service Agreement”) with Regus to lease office space at in Hoboken, New Jersey. Per the terms of the Office Service Agreement, the monthly rent payments are $1. The Company ~~had rent expense~~was required to pay a security deposit of ~~$1 during~~$2, which is the ~~quarter ended September 30, 2017~~equivalent to two months of rent. The Office Service Agreement commenced on January 27, 2020, and ~~$3 for~~terminated on July 31, 2020, thereafter the ~~nine months ended September 30, 2017.~~lease has been continuing on a month-to-month basis with either party being able to terminate the agreement by providing one months’ advance written notice of termination.

~~Subsequent events~~

~~Registration of Certain Common Shares and Warrants (S-3 & S-8)~~

On ~~October 24, 2017,~~August 1, 2023, the Company ~~filed~~entered into a ~~S-3 registration~~second Office Service Agreement (the “Second Office Service Agreement”) with Regus to lease office space in Dublin, Ireland. Per the terms of ~~common~~the Second Office Service Agreement, the monthly rent payments are $2. The Company was required to pay a security deposit of $5, which is the equivalent of two months rent. The Second Office Service Agreement commenced on August 1, 2023 and terminates on January 31, 2025, thereafter the lease may continue on a month-to-month basis with either party being able to terminate the agreement by providing one months’ advance written notice of termination.

The Second Office Service Agreement does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate consisting of the current prime rate plus 150 basis points for operating leases that

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares ~~pursuant~~in thousands, except per share information)

commenced after August 2023. The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.


		September 30, 2023

Remaining lease terms (in months)		16
Discount rate		10	%

Maturities of lease liabilities as of September 30, 2023 were as follows (in thousands):
Year Ending December 31,
2023 (remaining three months)	$	6
2024		23
2025		2
		31
Less imputed interest		2
Total lease liabilities	$	29

Current operating lease liabilities	$	21
Non-current operating lease liabilities		8
Total lease liabilities	$	29

7. Term Loans

On August 1, 2022, the Company entered into the SPA with the Investor in connection with the issuance of up to $45,000 of Notes, issuable in multiple tranches. On August 19, 2022, the Company closed the initial tranche of $5,000, which has an initial conversion price equal to $8.11 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to the announcement of the SPA. In connection with the first closing, the Company repaid in full its secured indebtedness with Bridge Bank in the amount of $5,000. The Notes become due on the maturity date, which is August 19, 2027.

On September 23, 2022, the Company closed the second tranche of the Note Financing in the amount of $20,000, which has an initial conversion price equal to $7.89 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to the Second Closing Trigger.

Subsequent to the funding of the Second Closing Note, and before December 31, 2023, the Company may ~~offer~~draw up to $20,000 of additional financing under the SPA, in one or more tranches of $10,000 upon mutual agreement of the Company and the Investor. The Subsequent Closing Notes will be convertible at a price per share equal to $7.89 per share, which price is calculated on the same basis as for the Second Closing Note.

A commitment fee of 2.0% of the Notes was payable under the SPA. Half of such fee was paid by the issuance on the first closing of warrants to purchase approximately 0.05 Fennec common shares and half was payable in cash or warrants of approximately 0.05 Fennec common shares, at our election, on the second closing. The Company chose to issue warrants to satisfy the payable on both the first and second closing. The warrants are exercisable at a price per share of $8.11 and both have a maturity date of August 19, 2027.

Cash interest on outstanding principal shall accrue at a rate of prime, plus 4.5% per annum, from ~~time~~the date of funding (12.75% at September 30, 2023 and 12% as of December 31, 2022). Cash interest is due on the first business day of each calendar quarter (“Interest Date”). In addition to ~~time,~~cash interest, payment-in-kind (“PIK”) interest will commence on funding date and accrue at a rate of 3.5% per annum. PIK interest will stop accruing on August 24, 2024. Any accrued PIK interest

Table of Contents

Fennec Pharmaceuticals Inc.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

shall remain outstanding and be payable on each Interest Date and be added to the outstanding principal amount. The Company has accrued $0.71 in PIK interest and has classified the PIK interest in long-term liabilities.

The Notes are convertible into fully paid, non-assessable shares of ~~our~~the Company’s common shares at any point after their issuance dates and before the maturity date. Any amount of the Notes may be converted into the Company’s common shares so long as it does not create partial shares. The conversion rate is determined by dividing the conversion amount by the conversion price. Provisions of the SPA create legal, valid and enforceable liens on, and security interests in, all of the Company’s and each of its subsidiaries assets.

Aggregate annual payments due on the SPA as of September 30, 2023 are as follows (in thousands):


Years Ending December 31,		Amount
2023	$	—
2024		—
2025		—
2026		—
2027		25,000
Payment in kind interest		937
Total future payments		25,937
Less: unamortized debt discount		(298)
Total term loan, net of debt discount	$	25,639

In the event of default or change of control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SPA facility is secured by all of the Company’s assets, including all capital stock ~~having an aggregate offering price~~held by the Company.

Debt issuance costs of up$175 were paid in cash for legal fees and to ~~$90.0 million. Under~~ the ~~Sales Agreement,~~Investor in 2022 and warrants valued at $441 were granted to the Investor to secure access to the SPA. These amounts were capitalized and are being amortized over the access period of the SPA. Upon closing on the First Closing Note and the Second Closing Note, the Company ~~may sell shares~~recorded a debt discount of $314, which was based on a pro-rata allocation of the issue costs to secure the SPA, reducing the capitalized amount by ~~any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under~~ the ~~Securities Act, as amended, including sales made directly on~~same amount. The debt discount is being amortized over the ~~NASDAQ, on any other existing trading market for our common stock or to or~~life of the SPA.

8. Subsequent Events

Management has evaluated subsequent events through ~~a market maker. The S-3 registration became effective on November 3, 2016. As of~~ the date of this filing and concluded there ~~have been~~are no ~~such sales.~~events of significance which require disclosure.

~~On October 24, 2017, the Company filed a S-8 registering its 2,631 outstanding options. The S-8 registration became effective upon filing.~~

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

~~CAUTIONARY STATEMENT~~

Caution Concerning Forward-Looking Statements

The following discussion ~~below contains forward-looking statements regarding~~and analysis of our financial condition and ~~our~~ results of operations ~~that are based upon~~should be read in conjunction with our ~~latest~~Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 29, 2023 (the “Annual Report”) and our unaudited interim condensed consolidated financial statements ~~which have been prepared~~and related notes appearing elsewhere in ~~accordance~~this Quarterly Report on Form 10-Q (the “Quarterly Report”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with ~~generally accepted accounting principles~~respect to the Company’s plans and strategy for its business, includes, and our officers and representatives may from time to time make, forward looking statements, within the ~~United States,~~meaning of the of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or ~~US GAAP,~~current fact. Forward-looking statements can be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “seeks,” “goals,” “projects,” “strategy,” “likely,” “will,” “would,” “could,” “can,” “may,” and ~~applicable U.S. Securities~~similar terms. Forward-looking statements are not guarantees of future performance and ~~Exchange Commission,~~our actual results may differ significantly from the results discussed in the forward-looking statements. As a result of many factors, including those factors set forth in Part I, Item 1A of the Annual Report under the heading “Risk Factors”, our actual results could differ materially from the results described in, or ~~SEC, regulations for financial information.~~ implied by, the forward-looking statements contained in the following discussion and analysis.

The ~~preparation of these unaudited interim~~following discussion should be read in conjunction with our Annual Report and the condensed consolidated financial statements ~~requires~~and accompanying notes included elsewhere in this report.

Overview

We are a commercial-stage biopharmaceutical company focused on our ~~management~~only product PEDMARK^®. On September 20, 2022, we received approval from the US Food and Drug Administration (“FDA”) for PEDMARK^® (sodium thiosulfate injection) to ~~make estimates~~reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and ~~judgments that affect~~older with localized, non-metastatic solid tumors. This approval makes PEDMARK^® the ~~reported amounts~~first and only treatment approved by the FDA in this area of ~~assets, liabilities, income~~unmet medical need. On October 17, 2022, we announced commercial availability of PEDMARK^® in the U. S. In addition, in January 2023, PEDMARK was included in the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for Adolescent and ~~expenses,~~Young Adult (AYA) Oncology with a category 2A recommendation.

In June 2023, we received European Commission Marketing Authorization for PEDMARQSI^TM (known as PEDMARK^® in the U.S.) Further, the decision included the receipt of a Pediatric Use Marketing Authorization (“PUMA”) in the European Union (“EU”) with up to 10 years of data and ~~related disclosure~~market protection. The Company is currently preparing for an EU launch of ~~contingent assets~~PEDMARQSI^TM in 2024.

In the U.S., we sell our product through an experienced field force including Regional Pediatric Oncology Specialists and ~~liabilities. We evaluate~~medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and our ~~estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions~~programs supporting patient access to PEDMARK^®. Now that we ~~believe~~have obtained applicable regulatory approval to ~~be reasonable. All amounts are presents~~sell PEDMARK^® in the ~~U.S. dollars~~U. S. and ~~in thousands except per share amounts.~~

~~Overview~~

~~Lead Product Candidate~~

~~The following is our only lead product candidate in~~authorization from the ~~clinical stage of development:~~

~~PEDMARK~~^TM (a unique formulation of sodium thiosulfate (STS)) – a water soluble thiol compound that acts as a chemical reducing agent, recently completed patient enrollment of two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

~~We continue to focus the Company’s resources on the development of PEDMARK~~^TM.

~~We have licensed from Oregon Health & Science University (“OHSU”) intellectual property rights~~European Commission Marketing Authorization for ~~the use of PEDMARK~~^TM ~~as a chemoprotectant, and are developing PEDMARK~~^TM ~~as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. Preclinical and clinical studies conducted by OHSU and others have indicated that PEDMARK~~^TM ~~can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. We have received Orphan Drug Designation in the United States for the use of PEDMARK~~PEDMARQSI^TM in the ~~prevention~~EU, we recognize there may still be a need to establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties, or other revenue.

Further, we have established Fennec HEARS™, a comprehensive single source program designed to connect PEDMARK^® patients to both patient financial and product access support. The program offers assistance and resources, regardless of ~~platinum-induced~~insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. Fennec HEARS™ also provides access to care coordinators that can answer insurance questions about coverage for PEDMARK^® and provide tips and resources for managing treatment.

Table of Contents

We received Orphan Drug Exclusivity for PEMARK in January 2023, which provides seven years of market exclusivity from its FDA approval on September 20, 2022 until September 20, 2029. We currently have three patents listed for PEDMARK^® in the FDA’s Orange Book. In September 2022, the USPTO issued Patent No. 11,291,728 (the “US ‘728 Patent”), in December 2022, the USPTO issued Patent No. 11,510,984 (“US ‘984 Patent”) and in April 2023, the USPTO issued Patent No. 11,671,793 (“US ‘793 Patent”) that covers PEDMARK^® pharmaceutical formulation. The US ‘728 Patent, US ‘984 Patent and US ‘793 Patent will expire in 2039. We are also pursuing additional patent applications in both the U.S. and internationally for PEDMARK^®.

PEDMARK^® Product Overview

PEDMARK^® is the first and only therapy approved by the FDA indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. Further, PEDMARQSI^TM, known as PEDMARK^® in the U.S. was granted marketing authorization by the European Commission in June 2023. PEDMARK^® is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK^® is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (“COG”) Protocol ACCL0431 and SIOPEL 6.

~~Hearing loss among~~In the U.S. and Europe, it is estimated that more than 10,000 children ~~receiving~~annually may receive platinum-based ~~chemotherapy is frequent, permanent and often severely disabling.~~chemotherapy. The incidence of ~~hearing loss in these children~~ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. ~~In addition, adults undergoing chemotherapy for several common malignancies, including ovarian cancer, testicular cancer,~~Infants and ~~particularly head~~young children that suffer ototoxicity at critical stages of development lack speech language development and ~~neck cancer~~literacy, and ~~brain cancer, often receive intensive platinum-based therapy~~older children and ~~may experience severe, irreversible hearing loss, particularly in the high frequencies.~~adolescents lack social-emotional development and educational achievement.

Investigators at OHSU have conducted Phase I and Phase II studies which have shown that STS reduces the hearing loss associated with platinum-based chemotherapy. In one study at OHSU, the need for hearing aids to correct high frequency hearing loss was reduced from about 50% to less than 5%.

~~STS~~PEDMARK^® has been studied by ~~cooperative~~co-operative groups in two Phase ~~III~~3 clinical studies of survival and reduction of ototoxicity, ~~the Clinical Oncology Group (“COG”) Protocol~~COG ACCL0431 and ~~the International Society of Pediatric Oncology (“~~SIOPEL ~~6”).~~6. Both studies have been completed. The COG ACCL0431 protocol enrolled ~~one of five~~ childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and ~~medulloblastoma.~~other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Cisplatin Induced Ototoxicity

~~In 2018, Fennec plans to pursue regulatory approval~~Cisplatin and other platinum compounds are essential chemotherapeutic agents for ~~PEDMARK~~^TM~~based on~~ the ~~data from SIOPEL 6 study along with the proof~~treatment of ~~principle data from COG ACCL0431. STS has received Orphan Drug Designation in the US in this setting and plans to pursue European Market Exclusivity for Pediatric Use upon approval.~~

~~SIOPEL 6~~

In October 2007, we announced that our collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial ("SIOPEL 6") to investigate whether STS reducesmany pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, ~~in standard risk hepatoblastoma (liver) cancer patients receiving cisplatin as a monotherapy.~~

which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.

The ~~study was initiated in October 2007 initially in~~incidence of ototoxicity depends upon the ~~United Kingdom~~dose and ~~completed enrollment at~~duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the end of 2014, 52 sites from 11 countries enrolled 109 evaluable patients. Under the terms of our agreement, SIOPEL will conduct and fund all clinical activities and Fennec will provide drug, drug distribution and pharmacovigilance, or safety monitoring, for the study was completed in December 2014 and the results of the trial were released in October 2017 at SIOP 2017.

~~The primary objectives of SIOPEL 6 are:~~

~~To assess the efficacy of STS to reduce the hearing impairment caused by cisplatin~~

~~To carefully monitor any potential impact of STS on response to cisplatin and survival~~

~~SIOPEL 6 - Results - October 2017~~

~~Background / Objectives:~~

~~Background: Bilateral high-frequency~~ hearing loss is a serious permanent side-effect of cisplatin therapy; particularly debilitating when occurring in young children. STS has been shown to reduce cisplatin induced hearing loss. SIOPEL 6 is a phase III randomised trial to assess the efficacy of STS in reducing ototoxicity inand can be costly over time. Infants and young children ~~treated with cisplatin (Cis) for SR-HB.~~that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.

~~Design / Methods:~~

Methods: Newly diagnosed patients with SR-HB, defined as tumour limited to PRETEXT I, II or III, no portal or hepatic vein involvement, no intra-abdominal extrahepatic disease, AFP >100ng/ml and no metastases, were randomised to Cis or Cis+STS for 4 preoperative and 2 postoperative courses. Cisplatin 80mg/m2 was administered over 6 hours, STS 20g/m2 was administered intravenously over 15 minutes exactly 6 hours after stopping cisplatin. Tumour response was assessed after 2 and 4 preoperative cycles with serum AFP and liver imaging. In case of progressive disease (PD), STS was to be stopped and doxorubicin 60mg/m2 combined to cisplatin. The primary endpoint is centrally reviewed absolute hearing threshold, at the age of ≥3.5 years by pure tone audiometry.

~~Results:~~

Results: One hundred and nine randomised patients (52 Cis and 57 Cis+STS) are evaluable. The combination of Cis+STS was generally well tolerated. With a follow up of 52months, 3yr EFS is Cis 78.8% and Cis+STS 82.1% 3yr OS is Cis 92.3% and Cis+STS 98.2%. Treatment failure defined as PD at 4 cycles was equivalent in both arms. Among the first 99 evaluable patients, hearing loss occurred in 30/45=67.0% under Cis and in 20/54=37.0% under Cis+STS, corresponding to a relative risk of 0.56(P=0.0033).

~~Conclusions:~~

This randomised phase III trial in SR-HB of cisplatin versus cisplatin plus sodium thiosulfate shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumour protection.

~~COG ACCL0431~~

In March 2008, we announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group (“COG ACCL0431”). The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether STS is an effective and safe means of preventing hearing loss in children receiving cisplatin-based chemotherapy for newly diagnosed germ cell, liver (hepatoblastoma), brain (medulloblastoma), nerve tissue (neuroblastoma) or bone (osteosarcoma) cancers. Eligible children, one to eighteen years of age, who are to receive cisplatin according to their disease-specific regimen and, upon enrollment in this study, will be randomized to receive STS or not. Efficacy of STS will be determined through comparison of hearing sensitivity at follow-up relative to baseline measurements using standard audiometric techniques. The Children’s Oncology Group is responsible for funding the clinical activities for the study and we are responsible for providing the drug, drug distribution and pharmacovigilance, or safety monitoring, for the study. The trial completed enrollment of 131 pediatric patients in the first quarter of 2012. The final results of COG ACCL0431 were published in~~Lancet Oncologyin December 2016.~~

~~COG ACCL0431 - Results~~

COG Study ACCL0431, “A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children,” finished enrollment of 131 of which 126 were eligible patients in Q1 2012. The patients had been previously diagnosed with childhood cancers.

~~The primary endpoint was to evaluate the efficacy of STS for prevention of hearing loss in children receiving cisplatin chemotherapy (hypothesis: 50% relative reduction in hearing loss).~~

~~Secondary endpoints included:~~

~~Compare change in mean hearing thresholds~~

~~Compare incidence of other Grade 3/4 toxicities (renal and hematological)~~

~~Monitor Event Free Survival (EFS) and Overall Survival (OS) in two groups~~

126 eligible subjects were enrolled with germ cell tumor (32), osteosarcoma (30), neuroblastoma (26), medulloblastoma (26), hepatoblastoma (7) or other (5). Of these, 104 subjects (64 male and 29 <5 years old) were evaluable for the primary endpoint.

Subjects were randomized either to no treatment (control) or treatment with STS 16 grams/m2 IV over 15 minutes 6 hours after each cisplatin dose. Hearing was measured using standard audiometry for age and data were reviewed centrally using American Speech-Language-Hearing Association criteria.

~~The proportion of subjects with hearing loss assessed at 4 weeks post the final cisplatin dose (primary endpoint)..~~

~~The proportion of hearing loss for STS vs. Control was 28.6% (14/49) vs. 56.4% (31/55), respectively (p=0.004).~~

~~In a predefined subgroup of patients less than 5 years old with 29 eligible subjects: STS vs. Control was 21.4% (3/14) vs. 73.3% (11/15), respectively (p=0.005)~~

~~Conclusions:~~

STS protects against cisplatin-induced hearing loss in children across a heterogeneous range of tumor types with even stronger efficacy in the protocol predefined subgroup of patients under five years old and is not associated with serious adverse events attributed to its use.

~~Capital Funding~~

We have not received and do not expect to have significant revenues from our product candidate until we are either able to sell our product candidate after obtaining applicable regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties or other revenue.

Liquidity

We generated a net loss of approximately ~~$4.8~~$13.4 million for the nine months ended September 30, ~~2017~~2023, and a net loss of ~~$1.6~~$16.9 million for the nine months ended September 30, 2016 (inclusive of a non-cash loss on derivatives of $0.34 million and $0.05 million non-cash gain on derivatives for the nine months ended September 30, 2017 and 2016, respectively).same period in 2022. As of September 30, ~~2017,~~2023, our accumulated deficit was approximately ~~$119.1~~$216.6 million ($~~114.3~~203.2 million at December 31, ~~2016)~~2022).

We believe that our cash and cash equivalents as of September 30, ~~2017,~~2023, which totaled ~~$9.7~~$12.4 million, cash from product sales, plus the remaining Petrichor Financing of $20 million in convertible notes subject to mutual agreement between us and Petrichor (see Note 1 and Note 7 to our unaudited interim condensed consolidated financial statements contained elsewhere in this Quarterly Report), will be sufficient to meet our cash requirements through and beyond current fiscal year. Because of our limited financial resources, we have postponed or terminated many of our previously planned or ongoing clinical development programs. We continue to pursue various strategic alternatives, including collaborations with other pharmaceutical and biotechnology companies. As a result, there is uncertainty of our ability to continue as a going concern.at least the next twelve months. Our projections of our capital requirements are subject to substantial ~~uncertainty. More~~uncertainty, and more capital than we ~~anticipated~~currently anticipate may be required thereafter. To finance our continuing operations,

Table of Contents

we ~~will~~may need to raise substantial additional funds through either the sale of additional equity, the issuance of debt, the establishment of collaborations, ~~that provide us with funding,~~ the out-license or sale of certain aspects of our intellectual property portfolio or from other sources. Given current economic conditions, we might not be able to raise the necessary capital or such funding may not be available on financially acceptable terms if at all. If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain research and development studies, consider business combinations or even shut down our operations.

Our operating expenses will depend on many factors, including the progress of our ~~drug development~~commercialization efforts abroad and ~~the implementation~~efficiency of ~~further cost reduction measures.~~our operations and current resources. Our research and development expenses, which include expenses associated with our clinical trials, drug manufacturing to support clinical programs, ~~salaries for research and development personnel, stock-based compensation,~~ consulting fees, sponsored research costs, toxicology studies, license fees, milestone payments, and other fees and costs related to the ~~development~~commercialization of our product, ~~candidate,~~ will depend on the availability of financial resources, the results of our clinical trials, and any directives from regulatory agencies, which are difficult to predict. Our general and administration expenses include expenses associated with the compensation of employees, stock-based compensation, professional fees, which include legal fees, consulting fees, insurance and other administrative matters associated in support primarily of our ~~drug development programs.~~commercialization of PEDMARK^®. Our selling and marketing expenses include remuneration of our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade shows, presentations, etc.), and any activities to support marketing and sales activities.

~~Use of Proceeds~~

On September 18, 2017, the Company’s registration statement on Form S-1 (File No. 333-219884) was declared effective, pursuant to which the Company registered the sale of 11,943,214 shares of common shares, including 1,383,331 shares issuable upon the exercise of outstanding warrants, all of which were to be sold by selling stockholders. All of the shares are to be sold by selling stockholders at prevailing market prices or privately negotiated prices. We did not receive any proceeds from the sale of securities by the selling stockholders. However, upon any exercise of the warrants we will receive the exercise price of the warrants.

Results of Operations

Three months ended September 30, ~~2017~~2023 versus three months ended September 30, ~~2016:~~2022:

Three Months Three Months
Ended Ended
In thousands of U.S. Dollars September 30, 2017 % September 30, 2016 % Change

Revenue $ - $ - $ -
Operating expenses:
Research and development 492 23 % 112 20 % 380
General and administration 1,694 77 % 452 80 % 1,242
Total operating expenses 2,186 100 % 564 100 % 1,622

Loss from operations (2,186 ) (564 ) (1,622 )

Unrealized (loss)/gain on derivatives (183 ) 19 (202 )
Sale of Eniluracil - 40 (40 )
Other gain 1 - 1
Interest income and other 16 3 13
Net loss and total comprehensive loss $ (2,352 ) $ (502 ) $ (1,850 )


	Three Months Ended				Three Months Ended
In thousands of U.S. Dollars	September 30, 2023		%		September 30, 2022		%		Change
PEDMARK® product sales, net		6,515				—				6,515
Cost of product sales		(331)	5	%		—	—	%		(331)
Gross profit	$	6,184			$	—			$	6,184
Operating expenses:
Research and development		12	—	%		846	11	%		(834)
Selling and marketing		3,384	47	%		—	—	%		3,384
General and administration		3,805	53	%		7,053	89	%		(3,248)
Total operating expense		7,201	100	%		7,899	100	%		(698)
Loss from operations		(1,017)				(7,899)				6,882
Unrealized loss on securities		(13)				(27)				14
Amortization expense		(72)				(64)				(8)
Interest expense		(856)				(119)				(737)
Unrealized foreign exchange loss		(11)				(4)				(7)
Interest income		102				24				78
Net loss	$	(1,867)			$	(8,089)			$	6,222

We reported net product sales for the three month period ended September 30, 2023 of $6,515 and gross profit of $6,184 after applying cost of product sales of $331. Research and development expenses ~~increased~~decreased by $834 for the three months ended September 30, ~~2017 over~~2023, compared to the same period in ~~2016 as the Company increased expenditures on PEDMARK~~^TM ~~development. This increase relates primarily to drug manufacturing~~2022. Our research and development activities ~~and preparations~~ for ~~registration activities.~~

~~General and administrative expenses increased over same~~this period ~~in 2016. The increase was primarily a result~~consisted of ~~the increase in non-cash equity compensation expenses for employees compared~~costs associated with investigator initiated clinical trials. During the same period in ~~2016.~~

~~The Company recorded an unrealized loss on derivatives~~2022 and prior to approval of ~~$183~~PEDMARK^®, manufacturing costs pertaining to PEDMARK^® were expensed to R&D expense in the period incurred, and following approval are reflected in inventory. Selling and marketing expenses were $3,384 for the three months ended September 30, ~~2017~~2023. Selling and marketing expenses include remuneration of our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade shows, presentations, etc.), and any activities to support marketing and sales activities. General and administrative expenses decreased by $3,248 compared to the same period in 2022, which was primarily driven by a ~~gain~~decrease of ~~$19~~non-cash employee remuneration of $1,000 and a decrease in legal expense by $707 as well as a major difference relating to the allocation of sales and marketing expenses to G&A for the period ended September 30, 2022 as we did not launch product until Q4 of 2022.

Interest expense increased $737 compared to the same period in 2022. This increase is associated with higher interest rates and $20,000 more in funded debt than in the same period in 2022. Further, we hold shares of Processa (NASDAQ: PCSA)

Table of Contents

which are marked to market each balance sheet date and unrealized gains or losses are recognized at that time. The value of the Processa shares held by the Company was down by $13 for the three month period ending September 30, 2023, as opposed to a decrease of $27 during the same period in 2022. Other losses were driven mainly by unrealized losses related to our foreign currency transactions. We have vendors that transact in Euros, Great British Pounds and Canadian Dollars. There was an increase of $7 in other losses for the three months ended September 30, 2023, compared to the same period in ~~2016. In the past, the derivative warrant liability was significant~~2022. Amortization expense is also a non-cash expense and ~~had the ability~~relates to produce large swings in non-cash gains and losses in any given period, depending upon market conditions. The remaining derivative liability on the balance sheet is associated with the Company’s Canadian denominated options. Although, there are very few derivative options remaining on the booksamortization of the ~~Company,~~deferred issuance costs of the ~~recent surge~~loan facilities with Petrichor. Amortization expense increased by $8 for the three months ended September 30, 2023 compared to the same period in ~~share price has had a noticeable effect on~~2022. Interest income was up $78 for the ~~value~~three months ended September 30, 2023, compared to the same period in 2022. This was driven mainly by higher interest rates for the three months ended September 30, 2023 compared to the same period in 2022.

Nine months ended September 30, 2023 versus nine months ended September 30, 2022:


	Nine Months Ended				Nine Months Ended
In thousands of U.S. Dollars	September 30, 2023		%		September 30, 2022		%		Change
PEDMARK® product sales, net	$	11,517			$	—			$	11,517
Cost of product sales		(574)	5	%		—	—	%		(574)
Gross profit		10,943				—				10,943
Operating expenses:
Research and development		24	—	%		3,414	21	%		(3,390)
Selling and marketing		8,255	38	%		—	—	%		8,255
General and administration		13,617	62	%		13,040	79	%		577
Total operating expenses		21,896	100	%		16,454	100	%		5,442
Loss from operations		(10,953)				(16,454)				5,501
Unrealized loss on securities		(43)				(126)				83
Amortization expense		(217)				(79)				(138)
Interest expense		(2,479)				(234)				(2,245)
Unrealized foreign exchange loss		3				(6)				9
Interest income		326				42				284
Net loss	$	(13,363)			$	(16,857)			$	3,494

We reported net product sales for the nine month period ended September 30, 2023 of ~~these derivatives. These option derivatives have been recorded at their fair value as a liability at issuance~~$11,517 and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as an unrealized gain/(loss). These options will continue to be reported as a liability until such time as they are exercised or expire. The fair valuegross profit of ~~these options is estimated using the Black-Scholes option-pricing model.~~

~~Our results~~$10,943 after applying cost of ~~operations~~product sales of $574. Research and development expenses decreased by $3,390 for the nine months ended September 30, ~~2017 versus nine months ended September 30, 2016 were as follows:~~

Nine Months Nine Months
Ended Ended
In thousands of U.S. Dollars September 30, 2017 % September 30, 2016 % Change

Revenue $ - $ - $ -
Operating expenses:
Research and development 1,050 24 % 298 17 % 752
General and administration 3,386 76 % 1,427 83 % 1,959
Total operating expenses 4,436 100 % 1,725 100 % 2,711

Loss from operations (4,436 ) (1,725 ) (2,711 )

Unrealized (loss)/gain on derivatives (340 ) 45 (385 )
Sale of Eniluracil - 40 (40 )
Other loss (4 ) (12 ) 8
Interest income and other 24 6 18
Net loss and total comprehensive loss $ (4,756 ) $ (1,646 ) $ (3,070 )

~~Total research~~2023, compared to the same period in 2022. Research activities, since the launch of PEDMARK^® have been limited to investigator initiated clinical trials. Selling and ~~development~~marketing expenses were ~~up by $752~~$8,255 for the nine months ended September 30, ~~2017~~2023. Selling and marketing expenses include remuneration of our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade shows, presentations, etc.), and any activities to support marketing and sales activities. General and administrative expenses increased by $577 over the same period in ~~2016.~~2022. This increase relates primarily to drug manufacturing activities and preparations for registration batches. General and administrative costs increased over the prior year in the same period primarily due to the issuance of equity based compensation.

~~Changes in the valuation of derivative liabilities are~~difference was primarily driven by volatility in the Company’s share price. Since February of 2017, the Company’s share price has increased. This has caused a significant fluctuation in the value of the derivative liabilities on our books. The result has been a 385an increase in non-cash ~~loss on derivative valuation~~equity compensation and higher wages in the amount of $1,448 for the nine months ended September 30, ~~2017~~2023 over the same period in ~~2016.~~

~~Quarterly Information~~

2022. For the nine months ended September 30, 2023, there was a decrease in legal expense of $399. The rest of the difference primarily relates to sales and marketing expenses being included in G&A in 2022 before product launch in Q4 of 2022.

The ~~following table presents selected condensed financial data~~unrealized loss on our shares of Processa for ~~quarters through~~the nine months ended on September 30, ~~2017, as prepared under US GAAP (U.S. dollars~~2023 was $43, which is in ~~thousands, except per share information):~~contrast to the $126 loss for the same period in 2022. Foreign currency transaction gain was $3 for the nine months ended September 30, 2023 ($6 loss for same period in 2022). Amortization expense was $217 for the nine months ended September 30, 2023, compared to $79 for the same period in 2022. Our amortization expense relates to the capitalized debt issuance costs associated with the Petrichor notes. Interest expense increased $2,245 for the nine months ended September 30, 2023, over same period in 2022. We replaced the $5 million loan facility with Bridge Bank with a larger facility, $25 million, with Petrichor. We took on this convertible debt load in a rising interest rate environment. Interest income was $284 higher for the nine months ended September 30, 2023, compared to the same period in 2022. This was driven mainly by higher interest rates for the nine months ended September 30, 2023 compared to the same period in 2022.

Period
Net Loss for the Period Basic Net Loss per
Common Share Diluted Net Loss per Common
Share
March 31, 2017 (806 ) (0.06 ) (0.06 )
June 30, 2017 (1,598 ) (0.11 ) (0.11 )
September 30, 2017 (2,352 ) (0.15 ) (0.15 )

Table of Contents

Liquidity and Capital Resources

U.S. Dollars in thousands
Selected Asset and Liability Data: September 30, 2017 December 31, 2016
Cash and cash equivalents $ 9,688 $ 3,926
Other current assets 200 46
Current liabilities excluding derivative liabilities 657 369
Derivative liabilities 373 33
Working capital⁽¹⁾ 9,231 3,603
⁽¹⁾ [Current assets – current liabilities excluding derivative liability]
Selected equity:
Common stock 83,062 74,515
Accumulated deficit (119,078 ) (114,322 )
Stockholders’ equity 8,858 3,570


	As of		As of
Selected Asset and Liability Data (thousands):	September 30, 2023		December 31, 2022
Cash and equivalents	$	12,399	$	23,774
Other current assets		6,547		2,954
Current liabilities		(3,913)		(4,608)
Working capital ⁽¹⁾		15,033		22,120
⁽¹⁾ [Current assets – current liabilities]

Selected Equity:
Common stock and additional paid in capital		204,789		199,388
Accumulated deficit		(216,563)		(203,200)
Stockholders’ deficit		(10,531)		(2,569)

Cash and cash equivalents were ~~$9,688~~$12,399 at September 30, ~~2017~~2023 and ~~$3,926~~$23,774 at December 31, ~~2016.~~2022. The ~~increase~~decrease in cash and cash equivalents between September 30, ~~2017~~2023 and December 31, ~~2016~~2022 is ~~primarily due~~the result of expenses related to ~~cash received from the exercise of various warrants and options and the completion of an equity financing in May 2017. These increases in cash were~~our normal operations, offset by inflows of cash ~~spent on research~~generated from net product sales of $11,517 and ~~development~~$969 from various option exercises. There was an increase of $3,593 in other current assets between December 31, 2022, and ~~general~~September 30, 2023.

Current liabilities decreased by $695 between December 31, 2022, and ~~administrative activities.~~September 30, 2023. The ~~Company received $7,571~~decrease was driven mainly by an increase in accounts payable ($551), offset by a large decrease of $1,268 in accrued expenses.

Working capital decreased between December 31, 2022, and September 30, 2023, by $7,087. The decrease relates to a net ~~of issuance costs~~cash inflow from product sales and various option exercises, offset by expenditures for operating activities for the ~~equity financing and $512 from the exercise of options and warrants. The Company issued a total of 2,214 shares as a result of these activities.~~

nine months ended September 30, 2023.

The following table illustrates a summary of cash flow data for the ~~three and~~ nine month ~~periods of September 30, 2017 and 2016:~~

Dollar and shares in thousands
Selected cash flow data: Three Months Ended
September 30, Nine months Ended
September 30,
2017 2016 2017 2016
Net cash used in operating activities $ (958 ) $ (544 ) $ (2,321 ) $ (1,513 )
Net cash provided by investing activities - - - -
Net cash provided by financing activities 414 - 8,083 5,108
Increase in cash and cash equivalents $ (544 ) $ (544 ) $ 5,762 $ 3,595

~~Net cash used in operating activities for the three months~~period ended September 30, 2017 was $958, as compared to $544 during the same period in 2016. This increase in cash outlays relates the preparation of registration including manufacturing of registration batches. Net cash provided by financing activities for the three months ended September 30, 2017 was $414 compared to $0 for the three months ended September 30, 2016. The $414 provided by financing activities, derived from the exercise of 207 options2023 and 21 warrants. For the same three-month period in 2016, there was no cash resulting from financing activities. Total decrease in cash and cash equivalents was $544 for the three months ended September 30, 2017, and for the same period in 2016.2022:


Selected Cash Flow Data	Nine Months Ended September 30,
(dollars and shares in thousands)	2023		2022
Net cash used in operating activities	$	(12,283)	$	(11,256)
Net cash provided by investing activities		—		—
Net cash provided by financing activities		908		19,908
Net cash flow	$	(11,375)	$	8,652

Net cash used in operating activities for the nine months ended September 30, ~~2017~~2023 and 2022, primarily reflected a net loss of $13,363 and $16,857, respectively. The nine month losses were adjusted for the add back of non-cash items consisting of $4,497 and $3,363, respectively, in stock-based compensation expense, with unrealized loss on securities of $43 and $126, respectively, and amortization expense of $217 and $79, respectively, for the nine months ended September 30, 2023, and 2022. For the nine months ended September 30, 2023 there was ~~$2,321, as compared to $1,513~~an increase in other current assets of $3,593 and a decrease of $756 during the same period in ~~2016. This~~2022. For the nine months ended September 30, 2023, there was a net decrease in current liabilities of $696, with a net increase ~~is due to increased~~of $1,273 during that same period in 2022. Nine month negative cash ~~outlays incurred~~flows from ~~research~~operating activities were $12,283 and ~~development in addition to increased general~~$11,256, respectively, for the periods ended September 30, 2023 and ~~administrative costs associated with the Company’s preparation for registration.~~2022. Net cash provided by financing activities for the nine months ended September 30, ~~2017 was $8,083 compared to $5,108 for~~2023, were $908 and $19,908, respectively. Net cash flows from the nine ~~months~~month period ended September 30, ~~2016. The $8,083 includes $7,571 net proceeds from the receipt of equity financing~~2023 and ~~$481~~2022, were negative $11,375, and ~~$31 in cash representing the exercise of 293 options and 31 warrants,~~positive $8,652, respectively. ~~Total increase in cash and cash equivalents was $5,762 for the nine months ended September 30, 2017 which is an increase of $2,167 over the same period in 2016.~~

We continue to pursue various strategic alternatives including collaborations with other pharmaceutical and biotechnology companies. Our projections of further capital requirements are subject to substantial uncertainty. Our working capital requirements may fluctuate in future periods depending upon numerous factors, including: our ability to obtain additional financial resources; our ability to enter into collaborations that provide us with up-front payments, milestones or other payments; ~~results of our research and development activities;~~ progress or lack of progress in our preclinical studies or clinical trials; unfavorable toxicology in our clinical ~~programs,~~

Table of Contents

programs; our drug substance requirements to support clinical programs; change in the focus, direction, or costs of our research and development programs; ~~personnel related costs;~~headcount expense; the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our patent claims; competitive and technological advances; the potential need to develop, acquire or license new technologies and products; our business development activities; new regulatory requirements implemented by regulatory authorities; the timing and outcome of any regulatory review process; and commercialization activities, if any.

Outstanding Share Information

~~We had cash and cash equivalents of approximately $9.7 million~~Our outstanding share data as of September 30, ~~2017.~~

~~Outstanding Share Information~~

~~The outstanding share data for our company as of September 30, 2017~~2023 and December 31, ~~2016~~2022 was as follows (in thousands):

	September 30, 2017		December 31, 2016		Change

								September 30,	December 31,
Outstanding Share Type								2023	2022	Change
Common shares		15,857		13,643		2,214		26,633	26,361	272
Warrants		1,362		1,383		(21	)	150	150	—
Stock options		2,361		2,427		(66	)	5,005	4,539	466
Total		19,580		17,453		2,127		31,788	31,050	738

Financial Instruments

We invest excess cash and cash equivalents in high credit quality investments held by financial institutions in accordance with our investment policy designed to protect the principal investment. At September 30, ~~2017,~~2023, we had approximately ~~$9.7 million~~$2,007 in our cash accounts and $10,392 in savings and money market accounts. WeWhile we have ~~not~~never experienced any loss or write down of our money market investments since ~~inception.~~

our inception, the amounts we hold in money market accounts are substantially above the $250 amount insured by the FDIC and may lose value.

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments may be made in U.S. or Canadian obligations and bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. ~~As our main purpose is research and development,~~Until we are cash flow positive from operations, we have chosen to avoid investments of a trading or speculative nature.

We classify fixed income investments with original maturities at the date of purchase greater than three months which mature at or less than twelve months as current. We carry investments at their fair value with unrealized gains and losses included in other comprehensive income (loss); however, we have not held any instruments that were classified as short-term investments during the periods presented in this Quarterly Report.

Off-Balance Sheet Arrangements

Since our inception, we have not had any material off-balance sheet arrangements. ~~In addition, we do not engage~~

Contractual Obligations and Commitments

None, other than the OHSU Agreement and lease agreements described in ~~trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged~~our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in ~~such activities.~~

~~Research~~this Quarterly Report, and ~~Development~~

~~Our research and development efforts have been focused on~~ the ~~development of PEDMARK~~^TM ~~since 2013.~~

We have established relationships with contract research organizations, universities and other institutions, which we utilize to perform many of the day-to-day activities associated with our drug development. Where possible, we have sought to include leading scientific investigators and advisors to enhance our internal capabilities. Research and development issues are reviewed internally by our executive management and supporting scientific team.

Research and development expenses for the three months ended September 30, 2017 and 2016 were $492 and $112, respectively and for the nine months then ended, $1,050 and $298 respectively. The Company has increased its research and development expenses related to PEDMARK^TMseverance amounts as ~~a result of the Company drug manufacturing activities related to the preparation for registration batches.~~

Our product candidate still requires significant, time-consuming and costly research and development, testing and regulatory clearances. In developing our product candidate, we are subject to risks of failure that are inherentdisclosed in the ~~development~~Annual Report.

Table of products based on innovative technologies. For example, it is possible that our product candidate will be ineffective or toxic, or will otherwise fail to receive the necessary regulatory clearances. There is a risk that our product candidate will be uneconomical to manufacture or market or will not achieve market acceptance. There is also a risk that third parties may hold proprietary rights that preclude us from marketing our product candidate or that others will market a superior or equivalent product. As a result of these factors, we are unable to accurately estimate the nature, timing and future costs necessary to complete the development of this product candidate. In addition, we are unable to reasonably estimate the period when material net cash inflows could commence from the sale, licensing or commercialization of such product candidate, if ever.Contents

Critical Accounting Policies and Estimates

~~The preparation~~A summary of ~~financial statements~~our critical accounting policies and use of estimates are presented in ~~conformity with US GAAP requires management~~Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operation” of our Annual Report. There have been no material changes to ~~make~~our critical accounting policies and use of estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the ~~reporting period. These estimates are based on assumptions and judgments that may be affected by commercial, economic and other factors. Actual results could differ from these estimates.~~nine months ended September 30, 2023.

~~Our accounting policies are consistent with those presented in our annual consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016.~~

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk

Not applicable.

~~Money Market Investments~~

We maintain an investment portfolio consisting of U.S. or Canadian obligations and bank securities and money market investments in compliance with our investment policy. We do not hold any mortgaged-backed investments in our investment portfolio. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

At September 30, 2017, we had $9.2 million in money market investments as compared to $3.9 million at December 31, 2016; these investments typically have minimal risk. The financial markets had been volatile resulting in concerns regarding the recoverability of money market investments, but those conditions have stabilized. We have not experienced any loss or write down of our money market investments since inception.

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Our risk associated with fluctuating interest rates on our investments is minimal and not significant to the results of operations. We currently do not use interest rate derivative instruments to manage exposure to interest rate changes. As the main purpose of the Company is research and development, we have chosen to avoid investments of a trade or speculative nature.

~~Foreign Currency Exposure~~

We are subject to foreign currency risks as we purchase goods and services which are denominated in Canadian dollars. To date, we have not employed the use of derivative instruments; however, we do hold Canadian dollars which we use to pay vendors in Canada and other corporate obligations. At September 30, 2017, the Company held approximately 352 thousand Canadian dollars (282 thousand as presented to U.S. dollars). At December 31, 2016, the company held approximately 87 thousand Canadian dollars (66 thousand as presented into U.S. dollars).

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures.

In connection with the preparation of this report, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the Company’s disclosureWe maintain "disclosure controls and procedures, ~~(as~~" as such term is defined in ~~Rules~~Rule 13a-15(e) ~~and 15d-15(e)~~ under the ~~Securities~~ Exchange Act, ~~of 1934 (“Exchange Act”)) as of September 30, 2017. Disclosure controls and procedures~~that are designed to ensure that information required to be disclosed by us in reports ~~filed~~that we file or ~~submitted~~submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in ~~Securities and Exchange Commission~~SEC rules and forms, and that such information is accumulated and communicated to our management, ~~including the~~our Chief Executive Officer and ~~the~~our Chief Financial Officer, as appropriate to allow timely decisions regarding required ~~disclosures.~~disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that ~~any~~disclosure controls and procedures, no matter how well ~~designed~~conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of ~~achieving~~ the ~~desired control objectives.~~disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. Based on ~~that~~this evaluation ~~the Company’s management concluded, as of~~at the end of the period covered by this ~~report,~~Quarterly Report on Form 10-Q, our Chief Executive Officer and our Chief Financial Officer, have concluded that ~~the Company’s~~our disclosure controls and procedures were ~~not~~ effective at the reasonable assurance level as ~~a result~~ of ~~having identified two material weaknesses in our internal control over financial reporting, as described in further detail below.~~

Our management has identified a control deficiency due to not maintaining an effective control environment, which is the foundation for the discipline and structure necessary for effective internal control over financial reporting, as evidenced by: (i) a lack of segregation of duties over individuals responsible for certain key control activities; (ii) an insufficient number of personnel appropriately qualified to perform control monitoring activities, including the recognition of the risks and complexities of transactions; and (iii) control activities that are not designed to respond to the risks identified. This control deficiency could result in a misstatement of balance sheet, income and cash flow statement accounts in our interim or annual financial statements that would not be detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

Our management has also identified another control deficiency that it believes constitutes a material weakness in our control over financial reporting. We did not maintain sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of US GAAP with regards to unusual transactions commensurate with our complexity and our financial accounting and reporting requirements. This control deficiency could result in a misstatement of the financial statements including disclosure that would not be prevented or detected on a timely basis.

~~We believe the control deficiencies described herein, individually and when aggregated, represent material weaknesses in our internal control over financial reporting at~~ September 30, 2017 since such deficiencies result in a reasonable possibility that a material misstatement in our annual or interim consolidated financial statements may not be prevented or detected on a timely basis by our internal controls.2023.

These material weaknesses did not result in any material misstatements to the financial statements. However, these material weaknesses could result in misstatement of the aforementioned account balances or disclosures that would result in material misstatements to the annual or interim consolidated financial statements that would not be prevented or detected.

To finance our continuing operations, we will need to raise additional funds beyond those from our most recent private placement in June 2017 and, as disclosed elsewhere in this report, there remains substantial doubt in our ability to continue as a going concern and the failure to obtain such funds might require us to further delay, scale back or eliminate certain research and development studies, consider business combinations, or even shut down our operations. If we are able to secure such additional financing, we anticipate hiring additional personnel with appropriate technical accounting knowledge, experience, and training in the application of U.S. GAAP to supplement our current accounting staff.

(b) Changes in Internal Control over Financial ~~Reporting~~

Reporting.

There ~~was~~have been no ~~change~~changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) ~~identified in connection with the evaluation of our internal control over financial reporting that occurred~~ during the ~~fiscal quarter ended September 30, 2017~~period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1. Legal ~~Proceedings.~~Proceedings.

For information about our legal proceedings, please see our Commitments and Contingencies footnote (Note 6) to our unaudited interim condensed consolidated financial statements included in Part 1. of this Quarterly Report.

~~None~~

Item 1A. Risk Factors.

Our Annual Report ~~on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 29, 2017 (the “Annual Report”),~~ includes a detailed discussion of our risk factors under the heading “PART I, Item 1A – Risk Factors.” You should carefully consider the risk factors discussed in our Annual Report, as well as other information in this ~~quarterly report.~~Quarterly Report. Any of these risks could cause our business, financial condition, results of operations and future growth prospects to suffer. We are not aware of any material changes from the risk factors previously disclosed.

Item 2. ~~Recent~~Unregistered Sales of ~~Unregistered Securities.~~Equity Securities and Use of Proceeds.

None.

~~The following table details grants~~29

Table of ~~stock options to various contractors, officers and directors of the Company for the period ended September 30, 2017:~~Contents

Date of Option Grant Number of Options Granted Strike Price $USD
August 17, 2017 21,150 $ 6.72

The options were issued in a private placement exempt under Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). The options were issued in USD denominated grants and are each exercisable for a period of 7 years from the grant date.

Item 3. ~~Default~~Defaults Upon Senior Securities.

None.

Item 4. Mine Safety ~~Disclosure.~~Disclosures.

Not applicable.

Item 5. Other Information.

On November 6, 2023, we issued a press release announcing our financial results for the quarter ended September 30, 2023. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.

~~None.~~

Item 6. Exhibits

~~Exhibit~~ ~~No.~~		~~Description~~
Exhibit No.		Description
~~31.1~~
31.1		Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2		Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1		Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

99.1		Press Release for Quarter Ended September 30, ~~2017~~2023 (filed herewith).

~~101.1~~ 101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

Table of Contents

SIGNATURES

Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Fennec Pharmaceuticals Inc.

Date: November ~~13, 2017~~9, 2023	By:	/s/ Rostislav Raykov
		Rostislav Raykov
		Chief Executive Officer
		(principal executive officer)

Date: November ~~13, 2017~~9, 2023	By:	/s/ Robert Andrade
		Robert Andrade
		Chief Financial Officer
		(principal financial and chief accounting officer)


British Columbia, Canada	20-0442384
(State or Other Jurisdiction of Incorporation or ~~Organization~~Organization)	~~20-0442384~~ (I.R.S. Employer Identification No.)

PO Box 13628, 68 TW Alexander Drive Research Triangle Park, North Carolina (Address of Principal Executive Offices)	27709 (Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	FENC	Nasdaq Capital Market

Large Accelerated Filer	¨ ☐		Accelerated Filer	¨ ☐
Non-Accelerated Filer	¨ ☒	~~(Do not check if smaller reporting company)~~	Smaller reporting company	x ☒
			Emerging growth company	¨ ☐

		~~Page~~
	Page
PART I: FINANCIAL INFORMATION		3

Item 1. Condensed Consolidated Financial Statements		3

Condensed Consolidated Balance Sheets (Unaudited) as of September 30, ~~2017(Unaudited)~~2023 and December 31, ~~2016~~2022		3

Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine ~~months~~Months Ended September 30, ~~2017~~2023 and ~~2016~~2022		4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the Three and Nine Months Ended September 30, 2023, and 2022	5

Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~Three and~~ Nine ~~months~~Months Ended September 30, ~~2017~~2023 and ~~2016~~2022		5 6
~~Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the Period Ended September 30, 2017~~		6
Notes to the Condensed Consolidated Financial Statements		7

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		14 23

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk		20 29

Item 4. Controls and Procedures		21 29

PART II: OTHER INFORMATION		22 29

Item 1. Legal Proceedings		22 29

Item 1A. Risk Factors		22 29

Item 2. ~~Recent~~Unregistered Sales of ~~Unregistered~~Equity Securities and Use of Proceeds		22 29

Item 3. ~~Default~~Defaults Upon Senior Securities		22 30

Item 4. Mine Safety ~~Disclosure~~Disclosures		22 30

Item 5. Other Information		22 30

Item 6. Exhibits		23 30
~~Signatures~~
Signatures	24 31

	x
	☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR ~~15(D)~~15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	¨
	☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	September 30, 2017			December 31,
	(unaudited)			2016

Assets

Current assets:
Cash and cash equivalents	$	9,688		$	3,926
Prepaid expenses		198			43
Other current assets		2			3
Total assets	$	9,888		$	3,972

Liabilities and stockholders' equity

Current liabilities:
Accounts payable	$	492		$	244
Accrued liabilities		165			125
Derivative instruments (Note 4)		373			33
Total current liabilities		1,030			402

Total liabilities		1,030			402

Commitments and contingencies (Note 8)

Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 15,857 shares issued and outstanding (2016-13,643)		83,062			74,515
Additional paid-in capital		43,631			42,134
Accumulated deficit		(119,078	)		(114,322	)
Accumulated other comprehensive income		1,243			1,243
Total stockholders’ equity		8,858			3,570
Total liabilities and stockholders’ equity	$	9,888		$	3,972

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2017			2016			2017			2016

Revenue	$	-		$	-		$	-		$	-

Operating expenses:
Research and development		492			112			1,050			298
General and administrative		1,694			452			3,386			1,427

Loss from operations		(2,186	)		(564	)		(4,436	)		(1,725	)

Other (expense) income :
Unrealized (loss)/gain on derivatives (Note 4)		(183	)		19			(340	)		45
Sale of Eniluracil		-			40			-			40
Other gain/(loss)		1			-			(4	)		(12	)
Interest income and other		16			3			24			6
Total other (expense)/income, net		(166	)		62			(320	)		79

Net loss	$	(2,352	)	$	(502	)	$	(4,756	)	$	(1,646	)

Basic net loss per common share	$	(0.15	)	$	(0.04	)	$	0.32		$	(0.13	)
Diluted net loss per common share	$	(0.15	)	$	(0.04	)	$	0.32		$	(0.13	)
Weighted-average number of common shares outstanding, basic		15,740			13,643			14,533			12,469
Weighted-average number of common shares outstanding, diluted		15,740			13,643			14,533			12,469

											Accumulated
					Additional						Other		Total
	Common Stock				Paid-in			Accumulated			Comprehensive		Stockholders'
	Number (Note 6)		Amount		Capital			Deficit			Income		Equity

Balance at December 31, 2016		13,643		74,515		42,134			(114,322	)		1,243		3,570
Stock options issued to employees		-		-		41			-			-		41
Stock options issued to contractors		-		-		56			-			-		56
Net loss		-		-		-			(806	)		-		(806	)
Balance at March 31, 2017		13,643		74,515		42,231			(115,128	)		1,243		2,861
Stock options issued to employees		-		-		461			-			-		461
Stock options issued to contractors		-		-		286			-			-		286
Exercise of stock options		86		191		(93	)		-			-		98
Rights offering		1,900		7,571		-			-			-		7,571
Net loss		-		-		-			(1,598	)		-		(1,598	)
Balance at June 30, 2017		15,629		82,277		42,885			(116,726	)		1,243		9,679
Stock options issued to employees		-		-		907			-			-		907
Stock options issued to contractors		-		-		210			-			-		210
Exercise of stock options		207		743		(360	)		-			-		383
Exercise of warrants		21		42		(11	)		-			-		31
Net loss		-		-		-			(2,352	)		-		(2,352	)
Balance at September 30, 2017		15,857		83,062		43,631			(119,078	)		1,243		8,858

	Three Months Ended September 30,					Nine Months Ended September 30,
Gain/(Loss) on Derivative Instruments	2017			2016		2017			2016
Derivatives expired March 29, 2016	$	-		$	-	$	-		$	41
Options to contractors		(183	)		19		(340	)		4
Gain/(loss) on Derivative Instruments	$	(183	)	$	19	$	(340	)	$	45

Contractor Options in $CAD	Three Month Period		Nine Month Period			Weighted-Average
Options in Thousands	Ending September 30, 2017					Exercise Price
Opening balance		39		40		$	1.81
Exercised		-		(1	)		2.05
Forfeited		-		-			-
Expired		-		-			-
Ending balance		39		39		$	1.80

	Number of			Weighted-Average
US Denominated Options	Options (thousands)			Exercise Price $USD
Outstanding December 31, 2016		1,428			1.93
Granted		-			-
Exercised		-			-
Forfeited		-			-
Outstanding at March 31, 2017		1,428			1.93
Granted		300			4.84
Exercised		(50	)		0.64
Forfeited		-			-
Outstanding at June 30, 2017		1,678			2.48
Granted		21			6.72
Exercised		(72	)		1.69
Forfeited		(3	)		2.79
Outstanding at September 30, 2017		1,624			2.57

	Three Months Ended September 30,
Black-Scholes Model Assumptions	2017			2016
Expected dividend		0.00	%		0.00	%
Risk free rate		2.04	%		1.27	%
Expected volatility		162	%		136	%
Expected life		7 years			7 years

	Fair Value Measurement at September 30, 2017
Assets/Liabilities Measured at Fair Value on a Recurring Basis	Quoted Price in Active Markets for Identical Instruments			Significant Other Observable Inputs		Significant Unobservable Inputs
	Level 1			Level 2		Level 3		Total
Assets
Cash and cash equivalents	$	440	⁽¹⁾	$	9,248	$	-	$	9,688
Liabilities
Derivative liabilities		-			-		373		373

	Three Months						Three Months
	Ended						Ended
In thousands of U.S. Dollars	September 30, 2017			%			September 30, 2016			%			Change

Revenue	$	-					$	-					$	-
Operating expenses:
Research and development		492			23	%		112			20	%		380
General and administration		1,694			77	%		452			80	%		1,242
Total operating expenses		2,186			100	%		564			100	%		1,622

Loss from operations		(2,186	)					(564	)					(1,622	)

Unrealized (loss)/gain on derivatives		(183	)					19						(202	)
Sale of Eniluracil		-						40						(40	)
Other gain		1						-						1
Interest income and other		16						3						13
Net loss and total comprehensive loss	$	(2,352	)				$	(502	)				$	(1,850	)

	Nine Months						Nine Months
	Ended						Ended
In thousands of U.S. Dollars	September 30, 2017			%			September 30, 2016			%			Change

Revenue	$	-					$	-					$	-
Operating expenses:
Research and development		1,050			24	%		298			17	%		752
General and administration		3,386			76	%		1,427			83	%		1,959
Total operating expenses		4,436			100	%		1,725			100	%		2,711

Loss from operations		(4,436	)					(1,725	)					(2,711	)

Unrealized (loss)/gain on derivatives		(340	)					45						(385	)
Sale of Eniluracil		-						40						(40	)
Other loss		(4	)					(12	)					8
Interest income and other		24						6						18
Net loss and total comprehensive loss	$	(4,756	)				$	(1,646	)				$	(3,070	)

Period	Net Loss for the Period			Basic Net Loss per Common Share			Diluted Net Loss per Common Share
March 31, 2017		(806	)		(0.06	)		(0.06	)
June 30, 2017		(1,598	)		(0.11	)		(0.11	)
September 30, 2017		(2,352	)		(0.15	)		(0.15	)

U.S. Dollars in thousands
Selected Asset and Liability Data:	September 30, 2017			December 31, 2016
Cash and cash equivalents	$	9,688		$	3,926
Other current assets		200			46
Current liabilities excluding derivative liabilities		657			369
Derivative liabilities		373			33
Working capital⁽¹⁾		9,231			3,603
⁽¹⁾ [Current assets – current liabilities excluding derivative liability]
Selected equity:
Common stock		83,062			74,515
Accumulated deficit		(119,078	)		(114,322	)
Stockholders’ equity		8,858			3,570

Date of Option Grant		Number of Options Granted				Strike Price $USD
August 17, 2017			21,150			$	6.72